<SEC-DOCUMENT>0001493152-21-029413.txt : 20211119
<SEC-HEADER>0001493152-21-029413.hdr.sgml : 20211119
<ACCEPTANCE-DATETIME>20211119171430
ACCESSION NUMBER:		0001493152-21-029413
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20211119
DATE AS OF CHANGE:		20211119

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ABEONA THERAPEUTICS INC.
		CENTRAL INDEX KEY:			0000318306
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				830221517
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-256850
		FILM NUMBER:		211429289

	BUSINESS ADDRESS:	
		STREET 1:		1330 AVENUE OF THE AMERICAS, 33RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
		BUSINESS PHONE:		646-813-4701

	MAIL ADDRESS:	
		STREET 1:		1330 AVENUE OF THE AMERICAS, 33RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PLASMATECH BIOPHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20140922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ACCESS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19960209

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHEMEX PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>form424b5.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>Filed Pursuant to Rule
424(b)(5)<BR>
Registration No. 333-256850</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Prospectus
Supplement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(to
Prospectus dated October 22, 2021)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$124,601,795</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="form424b5_01.jpg" ALT="" STYLE="height: 111px; width: 350px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into an Open Market Sale Agreement<SUP>SM</SUP> dated August 17, 2018, as amended on November 19, 2021 (the &ldquo;Sale
Agreement&rdquo;), with Jefferies LLC (the &ldquo;Agent&rdquo;), relating to the sale of shares of our common stock offered by this prospectus
supplement and the accompanying prospectus. In accordance with the terms of the Sale Agreement, we may offer and sell shares of our common
stock having an aggregate offering price of up to $150,000,000 from time to time through the Agent acting as sales agent, at our discretion,
pursuant to this prospectus supplement and the accompanying prospectus. In addition, as of the date of this prospectus supplement, we
had issued and sold shares of our common stock having an aggregate offering price of $25,398,204.63 pursuant to the Sale Agreement under
Registration Statement No. 333-224867, under a prior prospectus dated June 7, 2018 and a related prospectus supplement dated August 17,
2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of our common stock, if any, under this prospectus supplement and the accompanying prospectus may be made in sales deemed to be &ldquo;at
the market offerings&rdquo; as defined in Rule 415 promulgated under the Securities Act of 1933, as amended (&ldquo;the Securities Act&rdquo;)
including sales made directly on or through the Nasdaq Capital Market, the existing trading market for our common stock, sales made to
or through a market maker other than on an exchange or otherwise, in negotiated transactions at market prices prevailing at the time
of sale or at prices related to such prevailing market prices, and/or any other method permitted by law. The Agent is not required to
sell any specific number or dollar amount of securities but will act as our sales agent using commercially reasonable efforts consistent
with its normal trading and sales practices, on mutually agreed terms between the Agent and us. Our common stock to which this prospectus
supplement relates will be sold through the Agent on any given day. There is no arrangement for funds to be received in any escrow, trust
or similar arrangement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation to the Agent for sales of common stock sold pursuant to the Sale Agreement will be 3.0% of the gross proceeds from each
such sale. In connection with the sale of the common stock on our behalf, the Agent may be deemed to be an &ldquo;underwriter&rdquo;
within the meaning of the Securities Act, and the Agent&rsquo;s compensation may be deemed to be underwriting commissions or discounts.
See &ldquo;Plan of Distribution&rdquo; for additional information regarding compensation to be paid to the Agent. We have also agreed
to provide indemnification and contribution to the Agent with respect to certain liabilities, including liabilities under the Securities
Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on the Nasdaq Capital Market under the symbol &ldquo;ABEO.&rdquo; On November 15, 2021, the last reported sale
price of our common stock on the Nasdaq Capital Market was $0.91 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 40%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investing
in our securities involves significant risks. Please read the information contained in or incorporated by reference under the heading
&ldquo;Risk Factors&rdquo; beginning on page S-4 of this prospectus supplement, and under similar headings in other documents filed after
the date hereof and incorporated by reference into this prospectus supplement and the accompanying prospectus.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed
upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal
offense.<BR>
<BR>
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jefferies
LLC</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
date of this prospectus supplement is November 19, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Table
of Contents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_001">About This Prospectus Supplement</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_002">Summary</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-2</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_003">The Offering</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_004">Risk Factors</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-4</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_005">Cautionary Note Regarding Forward-Looking Statements</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-5</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_006">Use of Proceeds</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-6</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_007">Dilution</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-7</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_008">Plan of Distribution</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-8</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_009">Legal Matters</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-8</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_010">Experts</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-8</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_011">Where You Can Find More Information; Incorporation by Reference</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-9</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 91%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Prospectus</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#g_002"><FONT STYLE="font-size: 10pt">About
    This Prospectus</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#g_003">Cautionary
    Note Regarding Forward-Looking Statements</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#g_004"><FONT STYLE="font-size: 10pt">The
    Company</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#g_005"><FONT STYLE="font-size: 10pt">Risk
    Factors</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#g_006"><FONT STYLE="font-size: 10pt">Use
    of Proceeds</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#g_007"><FONT STYLE="font-size: 10pt">Plan
    of Distribution</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#g_008"><FONT STYLE="font-size: 10pt">General
    Description of Securities That We May Sell</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">8</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#g_009"><FONT STYLE="font-size: 10pt">Description
    of Our Common Stock</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#g_010"><FONT STYLE="font-size: 10pt">Description
    of Our Preferred Stock</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#g_011"><FONT STYLE="font-size: 10pt">Description
    of Our Warrants</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#g_012"><FONT STYLE="font-size: 10pt">Description
    of Our Debt Securities</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#g_013"><FONT STYLE="font-size: 10pt">Where
    You Can Find More Information; Incorporation by Reference</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#g_014"><FONT STYLE="font-size: 10pt">Legal
    Matters</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#g_015"><FONT STYLE="font-size: 10pt">Experts</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_001"></A>ABOUT
THIS PROSPECTUS SUPPLEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement and the accompanying prospectus relate to the offering of our common stock. You should read this prospectus supplement,
the accompanying prospectus, the documents incorporated by reference into this prospectus supplement and the accompanying prospectus,
and any free writing prospectus that we may authorize for use in connection with this offering, in their entirety before making an investment
decision. You should also read and consider the information in the documents to which we have referred you in the section of this prospectus
supplement entitled &ldquo;Where You Can Find More Information; Incorporation by Reference.&rdquo; These documents contain important
information that you should consider when making your investment decision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
document is in two parts. The first part is this prospectus supplement, which describes the specific terms of the offering of the common
stock and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference into
this prospectus supplement and the accompanying prospectus. The second part, the accompanying prospectus, including the documents incorporated
by reference into the accompanying prospectus, provides more general information, some of which may not apply to this offering. Generally,
when we refer to this prospectus, we are referring to the combined document consisting of this prospectus supplement and the accompanying
prospectus. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the
information contained in the accompanying prospectus or in any document incorporated by reference into the accompanying prospectus that
was filed with the Securities and Exchange Commission (&ldquo;SEC&rdquo;) before the date of this prospectus supplement, on the other
hand, you should rely on the information in this prospectus supplement. If any statement in one of these documents is inconsistent with
a statement in another document having a later date, the statement in the document having the later date modifies or supersedes the earlier
statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are responsible for the information contained in, or incorporated by reference into, this prospectus supplement, the accompanying prospectus
and in any free writing prospectus that we may authorize for use in connection with this offering. We have not, and the Agent has not,
authorized any other person to provide you with different information, and neither we nor the Agent takes any responsibility for any
other information that others may give you.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not, and the Agent is not, making an offer to sell or soliciting an offer to buy our common stock in any jurisdiction in which an
offer or solicitation is not authorized or in which the person making that offer or solicitation is not qualified to do so or to anyone
to whom it is unlawful to make an offer or solicitation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should assume that the information appearing in this prospectus supplement, the accompanying prospectus, the documents incorporated by
reference into this prospectus supplement and the accompanying prospectus, and in any free writing prospectus that we may authorize for
use in connection with this offering, is accurate only as of the date of those respective documents. Our business, financial condition,
results of operations and prospects may have changed since those dates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
the context otherwise requires or as otherwise expressly stated, references in this prospectus to the terms &ldquo;the Company,&rdquo;
&ldquo;Abeona,&rdquo; &ldquo;we,&rdquo; &ldquo;our&rdquo; and &ldquo;us&rdquo; or other similar terms mean Abeona Therapeutics Inc. and
its subsidiaries, unless we state otherwise, or the context indicates otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_002"></A>SUMMARY</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>This
summary highlights information contained elsewhere or incorporated by reference in this prospectus supplement and the accompanying prospectus.
This summary does not contain all of the information that you should consider before deciding to invest in our common stock. You should
read this entire prospectus supplement and the accompanying prospectus carefully, including the &ldquo;Risk Factors&rdquo; section contained
in this prospectus supplement, our financial statements and the related notes thereto, and the other documents incorporated by reference
in this prospectus supplement and the accompanying prospectus.</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Overview</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage biopharmaceutical company developing gene and cell therapies for life-threatening rare genetic diseases. Our lead
clinical programs consist of (i) EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa (&ldquo;RDEB&rdquo;),
(ii) ABO-102, an adeno-associated virus (&ldquo;AAV&rdquo;)-based gene therapy for Sanfilippo syndrome type A (&ldquo;MPS IIIA&rdquo;),
and (iii) ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B (&ldquo;MPS IIIB&rdquo;). We continue to develop additional
AAV-based gene therapies designed to treat ophthalmic and other diseases, next-generation AAV-based gene therapies using the novel AIM&trade;
capsid platform that we have exclusively licensed from the University of North Carolina at Chapel Hill, and internal AAV vector research
programs. A number of our product candidates are eligible for orphan drug designation, breakthrough therapy designation, or other expedited
review processes in the U.S., Europe, Japan, or other world markets. Our pipeline includes three programs in clinical development&mdash;EB-101,
ABO-101 and ABO-102&mdash; for which we hold several U.S. and European Union regulatory designations, and a pipeline of additional earlier
stage programs.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
Information</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were incorporated in 1974. On October 24, 2014, we changed our name to PlasmaTech Biopharmaceuticals, Inc., and on June 19, 2015, we
changed our name to Abeona Therapeutics Inc. to reflect our broader rare disease commitment. Our principal executive office is located
at 1330 Avenue of the Americas, 33rd Floor, New York, NY 10019, and our telephone number is +1 (646) 813-4701. Our website is www.abeonatherapeutics.com.
We do not incorporate by reference into this prospectus supplement the information on our website, and you should not consider it as
part of this prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_003"></A>THE
OFFERING</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock Offered</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 65%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    of our common stock having an aggregate offering price of up to $124,601,795.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manner
    of Offering</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;At
    the market offering&rdquo; that may be made from time to time through the Agent, as sales agent. See &ldquo;Plan of Distribution&rdquo;
    on page S-8 of this prospectus supplement for a more complete description of the manner of offering.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
    Agent</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jefferies
    LLC</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use
    of Proceeds</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    expect to use the net proceeds of this offering, if any, to fund continued development of pipeline products, as well as for working
    capital and general corporate purposes. General corporate purposes may include repayment of debt, acquisitions, additions to working
    capital, capital expenditures, research and development and investments in our subsidiaries. See &ldquo;Use of Proceeds&rdquo; on
    page S-6 of this prospectus supplement for a more complete description of the intended use of proceeds from this offering.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
    Factors</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing
                                            in our securities involves significant risks. Please read the information contained in or
                                            incorporated by reference under the heading &ldquo;Risk Factors&rdquo; beginning on page
                                            S-4 of this prospectus supplement, and under similar headings in other documents filed after
                                            the date hereof and incorporated by reference into this prospectus supplement and the accompanying
                                            prospectus.</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq
    Capital Market symbol</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABEO</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_004"></A>RISK
FACTORS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>An
investment in our securities involves risks. We urge you to consider carefully the risks described below, and in the documents incorporated
by reference in this prospectus supplement and the accompanying prospectus, before making an investment decision, including those risks
identified under &ldquo;Item IA. Risk Factors&rdquo; in our Annual Report on Form 10-K for the year ended December 31, 2020 and in our
Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, which are incorporated by reference in this prospectus supplement
and which may be amended, supplemented or superseded from time to time by other reports that we subsequently file with the SEC. Additional
risks, including those that relate to any particular securities we offer, may be included in a future prospectus supplement or free writing
prospectus that we authorize from time to time, or incorporated by reference into this prospectus supplement or the accompanying prospectus
in connection with this offering. If any of these risks actually occur, our business, financial condition, results of operations or cash
flow could be seriously harmed. This could cause the trading price of our common stock to decline, resulting in a loss of all or part
of your investment. Please also read carefully the section below entitled &ldquo;Cautionary Note Regarding Forward-Looking Statements.&rdquo;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
Related to this Offering</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of our common stock in this offering, or the perception that such sales may occur, could cause the market price of our common stock to
fall.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issuance and sale from time to time of shares of common stock, or our ability to issue these new shares of common stock in this offering,
could have the effect of depressing the market price of our common stock. We cannot predict the effect that future sales of our common
stock would have on the market price of our common stock.</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management will have broad discretion over the use of the net proceeds from this offering, you may not agree with how we use the proceeds,
and the proceeds may not be invested successfully.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management will have broad discretion as to the use of the net proceeds from any offering by us and could use them for purposes other
than those contemplated at the time of this offering. Accordingly, you will be relying on the judgment of our management with regard
to the use of these net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds
are being used appropriately. It is possible that the proceeds will be invested in a way that does not yield a favorable, or any, return
for Abeona.</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may experience immediate and substantial dilution in the book value per share of the common stock you purchase in the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
offering price per share in this offering may exceed the pro forma net tangible book value per share of our common stock outstanding
prior to this offering. Based on an assumed public offering price of $0.91 per share, which was the last reported sale price of our common
stock on the Nasdaq Capital Market on November 15, 2021, you will experience immediate dilution of $0.21 per share, representing the
difference between our pro forma as adjusted net tangible book value per share as of September 30, 2021, after giving effect to this
offering and the assumed offering price. The exercise of outstanding stock options will result in further dilution of your investment.
See the section below entitled &ldquo;Dilution&rdquo; for a more detailed illustration of the dilution you would incur if you participate
in this offering.</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will require additional capital funding, the receipt of which may impair the value of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future capital requirements depend on many factors, including our research, development, sales, and marketing activities. We will need
to raise additional capital through public or private equity or debt offerings or through arrangements with strategic partners or other
sources in order to continue to develop our drug candidates. There can be no assurance that additional capital will be available when
needed or on terms satisfactory to us, if at all. To the extent we raise additional capital by issuing equity securities, our stockholders
may experience substantial dilution and the new equity securities may have greater rights, preferences, or privileges than our existing
common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_005"></A>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement, the accompanying prospectus, and the other documents we have filed with the SEC that are incorporated herein by
reference contain forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements
of historical facts, regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects,
plans, objectives of management or other financial items are forward-looking statements. The words &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo;
&ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;seek,&rdquo; &ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;plan,&rdquo; &ldquo;predict,&rdquo;
&ldquo;project,&rdquo; &ldquo;will,&rdquo; &ldquo;would&rdquo; and similar expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these identifying words.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place
undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations
disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this
prospectus supplement, particularly as set forth and incorporated by reference in the &ldquo;Risk Factors&rdquo; section above, that
we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking
statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, collaborations, or
investments we may make. You should read this prospectus supplement, the accompanying prospectus, and the documents that we incorporate
by reference in this prospectus supplement completely and with the understanding that our actual future results may be materially different
from what we expect. We do not assume any obligation to update any forward-looking statements, except as otherwise required by law. We
advise you, however, to consult any further disclosures we make on related subjects in our future annual reports on Form 10-K, quarterly
reports on Form 10-Q and current reports on Form 8-K we file with or furnish to the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_006"></A>USE
OF PROCEEDS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to use the net proceeds from this offering to fund continued development of pipeline products, as well as for working capital
and general corporate purposes. General corporate purposes may include research and development, additions to working capital, capital
expenditures, acquisitions and investments in our subsidiaries. The amounts and timing of our use of the net proceeds from the sale of
securities in this offering will depend on a number of factors, such as the timing and progress of trials of our clinical and pre-clinical
product candidates and our development efforts, the timing and progress of any partnering efforts, technological advances, and the competitive
environment for our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this prospectus supplement, we cannot specify with certainty all of the particular uses for the net proceeds to us from
this offering. Accordingly, our management will have broad discretion in the timing and application of these proceeds. Pending application
of the net proceeds as described above, we may invest the net proceeds of this offering in a variety of capital preservation investments,
including but not limited to short-term, interest-bearing investment grade securities, money market accounts, certificates of deposit
and direct or guaranteed obligations of the U.S. government.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_007"></A>DILUTION</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you invest in this offering, your ownership interest will be diluted to the extent of the difference between the public offering price
per share and the as adjusted net tangible book value per share after giving effect to this offering. We calculate net tangible book
value per share by dividing the net tangible book value, which is tangible assets less total liabilities, by the number of outstanding
shares of our common stock. Dilution represents the difference between the portion of the amount per share paid by purchasers of shares
in this offering and the as adjusted net tangible book value per share of our common stock immediately after giving effect to this offering.
Our net tangible book value as of September 30, 2021 was approximately $46.2 million, or $0.45 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Without
taking into account any other changes in net tangible book value after September 30, 2021, after giving effect to the sale of our common
stock pursuant to this prospectus supplement and accompanying prospectus in the aggregate amount of $124,601,795 at an assumed offering
price of $0.91 per share, the last reported sale price of our common stock on the Nasdaq Capital Market on November 15, 2021, and after
deducting commissions and estimated aggregate offering expenses payable by us, our net tangible book value as of September 30, 2021 would
have been $166.9 million, or $0.70 per share of common stock. This represents an immediate increase in the net tangible book value of
$0.25 per share to our existing stockholders and an immediate dilution in net tangible book value of $0.21 per share to new investors.
The following table illustrates this per share dilution:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%">Assumed offering price per share</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">0.91</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Net tangible book value per share as of September 30, 2021</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.45</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Increase per share attributable to new investors</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.25</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">As adjusted net tangible book value per share as of September 30, 2021 after
    giving effect to this offering</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.70</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">Dilution per share to new investors purchasing shares in this offering</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right"></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.21</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares of our common stock to be outstanding after this offering is based on 101,867,539 shares of our common stock
outstanding as of September 30, 2021, which amount excludes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,755,196
    shares issuable upon the exercise of stock options outstanding as of September 30, 2021 at a weighted average exercise price of&thinsp;
    $1.58 per share; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,617,138
    shares of common stock reserved for future issuance under our equity incentive plans.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_008"></A>PLAN
OF DISTRIBUTION</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into an Open Market Sale Agreement<SUP>SM</SUP>, as amended by Amendment No. 1 thereto, dated as of November 19, 2021, with
Jefferies LLC (the &ldquo;Agent&rdquo;), under which we may issue and sell shares of our common stock from time to time through the Agent
acting as sales agent, subject to certain limitations, including the number of shares registered under the registration statement to
which the offering relates. As of November 19, 2021, we have issued and sold shares of our common stock having an aggregate offering
price of $25,398,204.63 pursuant to the Sale Agreement under Registration Statement No. 333-224867, under a prior prospectus and related
prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of our common stock, if any, under this prospectus supplement and the accompanying prospectus may be made in sales deemed to be &ldquo;at
the market offerings&rdquo; as defined in Rule 415 promulgated under the Securities Act, including sales made directly on or through
the Nasdaq Capital Market, the existing trading market for our common stock, sales made to or through a market maker other than on an
exchange or otherwise, in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing
market prices, and/or any other method permitted by law. We may instruct the Agent not to sell our common stock if the sales cannot be
effected at or above the price designated by us from time to time. We or the Agent may suspend the offering of our common stock upon
notice and subject to other conditions. As an agent, the Agent will not engage in any transactions that stabilize the price of our common
stock. Our common stock to which this prospectus supplement relates will be sold through only one Agent on any given day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
time we wish to issue and sell common stock under the Sale Agreement with the Agent, we will notify the Agent of the number of shares
to be issued, the dates on which such sales are anticipated to be made, any minimum price below which sales may not be made and other
sales parameters as we deem appropriate. Once we have so instructed the Agent, unless the Agent declines to accept the terms of the notice,
the Agent has agreed to use its commercially reasonable efforts consistent with its normal trading and sales practices to sell such shares
up to the amount specified on such terms. The Agent&rsquo;s obligations under the Sale Agreement to sell our common stock are subject
to a number of conditions that we must meet.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will pay the Agent commissions for its services in acting as agent in the sale of our common stock. The Agent will be entitled to compensation
at a commission rate equal to 3.0% of the gross sales price per share sold. Because there is no minimum offering amount required as a
condition to closing this offering, the actual total public offering amount, commissions, and proceeds to us, if any, are not determinable
at this time. In addition, we have agreed to reimburse the Agent for fees and disbursements paid to its legal counsel, in amounts not
to exceed $50,000 in both cases, in connection with the original Sale Agreement and Amendment No. 1 thereto. In accordance with FINRA
Rule 5110, these reimbursed fees and expenses are deemed sales compensation for this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
estimate that the total expenses for the offering, excluding compensation payable to the Agent under the terms of the Sale Agreement
and Amendment No. 1 thereto, will be approximately $100,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Settlement
for sales of our common stock will occur on the second business day following the date on which any sales are made, or on some other
date that is agreed upon by us and the Agent in connection with a particular transaction, in return for payment of the net proceeds to
us. There is no arrangement for funds to be received in an escrow, trust, or similar arrangement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the sale of the common stock on our behalf, the Agent may, and will with respect to sales effected in an &ldquo;at the
market offering,&rdquo; be deemed to be an &ldquo;underwriter&rdquo; within the meaning of the Securities Act, and the Agent&rsquo;s
compensation may be deemed to be underwriting commissions or discounts. We have agreed to provide indemnification and contribution to
the Agent against certain civil liabilities, including liabilities under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
offering pursuant to the Sale Agreement will terminate upon the earlier of (i) the issuance and sale of all shares of our common stock
subject to the Sale Agreement, or (ii) the termination of the Sale Agreement as permitted therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Agent and its affiliates may in the future provide various investment banking and other financial services for us and our affiliates,
for which services they may in the future receive customary fees. To the extent required by Regulation M, the Agent will not engage in
any market making activities involving our common stock while the offering is ongoing under this prospectus supplement.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_009"></A>LEGAL
MATTERS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
validity of the common stock offered hereby will be passed upon for us by Morgan, Lewis &amp; Bockius LLP, Boston, Massachusetts. Covington
&amp; Burling LLP, New York, New York, will act as counsel to the Agent in connection with this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_010"></A>EXPERTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements, incorporated by reference from the Company&rsquo;s Annual Report on Form 10-K for the fiscal year
ended December 31, 2020, have been audited by Whitley Penn LLP, an independent registered public accounting firm, as stated in their
report, which is incorporated herein by reference. Such financial statements have been so incorporated in reliance upon the report of
such firm given upon their authority as experts in accounting and auditing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_011"></A>WHERE
YOU CAN FIND MORE INFORMATION; INCORPORATION BY REFERENCE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
file annual, quarterly, and current reports, proxy statements and other information with the SEC. The SEC maintains a website at www.sec.gov
that contains reports, statements, and other information about issuers, such as us, who file electronically with the SEC. We maintain
a website at www.abeonatherapeutics.com. However, the information on our website is not incorporated by reference into this prospectus
supplement and the accompanying prospectus and you should not consider it a part of this prospectus supplement or the accompanying prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC allows us to &ldquo;incorporate by reference&rdquo; into this prospectus supplement the information in other documents that we file
with it. This means that we can disclose important information to you by referring you to those documents. The information incorporated
by reference is considered to be a part of this prospectus supplement, and information in documents that we file later with the SEC will
automatically update and supersede information contained in documents filed earlier with the SEC or contained in this prospectus supplement.
We incorporate by reference into this prospectus supplement the documents listed below; provided, however, that we are not incorporating,
in each case, any documents or information deemed to have been furnished and not filed in accordance with SEC rules:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Annual Report on Form 10-K for the year ended <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/318306/000149315221006705/form10-k.htm" STYLE="-sec-extract: exhibit">December 31, 2020</A> (filed on March 24, 2021) (including the information in Part III
    incorporated by reference from the Company&rsquo;s Definitive Proxy Statement on Schedule 14A, filed on <A HREF="https://www.sec.gov/Archives/edgar/data/318306/000114036121012309/nc10022188x2_def14a.htm" STYLE="-sec-extract: exhibit">April 9, 2021</A>);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Quarterly Reports on Form 10-Q for the quarterly periods ended <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/318306/000149315221011822/form10-q.htm" STYLE="-sec-extract: exhibit">March 31, 2021</A> (filed on May 17, 2021), <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/318306/000149315221017978/form10-q.htm" STYLE="-sec-extract: exhibit">June 30, 2021</A> (filed on July
    28, 2021) and <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/318306/000149315221028506/form10-q.htm" STYLE="-sec-extract: exhibit">September 30, 2021</A> (filed on November 15, 2021);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Current Reports on Form 8-K filed on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/318306/000149315221002234/form8-k.htm" STYLE="-sec-extract: exhibit">February 1, 2021</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/318306/000149315221006620/form8-k.htm" STYLE="-sec-extract: exhibit">March 23, 2021</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/318306/000149315221007196/form8-k.htm" STYLE="-sec-extract: exhibit">March 30, 2021</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/318306/000149315221009122/form8-k.htm" STYLE="-sec-extract: exhibit">April 19, 2021</A> (as amended on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/318306/000149315221013235/form8-ka.htm" STYLE="-sec-extract: exhibit">May 28, 2021</A>),
    <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/318306/000149315221013234/form8-k.htm" STYLE="-sec-extract: exhibit">May 28, 2021</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/318306/000149315221016996/form8-k.htm" STYLE="-sec-extract: exhibit">July 16, 2021</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/318306/000149315221019797/form8-k.htm" STYLE="-sec-extract: exhibit">August 13, 2021</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/318306/000149315221023269/form8-k.htm" STYLE="-sec-extract: exhibit">September 21, 2021</A> and <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/318306/000149315221028327/form8-k.htm" STYLE="-sec-extract: exhibit">November 15, 2021</A>; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    description of our common stock, par value $0.01 per share contained in our Registration Statement on <A HREF="https://www.sec.gov/Archives/edgar/data/318306/000114420414065030/v393203_8a12b.htm" STYLE="-sec-extract: exhibit">Form 8-A</A>, dated and filed with
    the SEC on November 4, 2014, as updated by <A HREF="https://www.sec.gov/Archives/edgar/data/318306/000149315220004015/ex4-4.htm" STYLE="-sec-extract: exhibit">Exhibit 4.4</A> to our Form 10-K for the fiscal year ended December 31, 2019, and including
    any amendments or reports filed with the SEC for the purpose of updating such description.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
reports and other documents we subsequently file pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the termination
of this offering, including all such documents we may file with the SEC after the date of the initial registration statement, but excluding
any information furnished to, rather than filed with, the SEC, will also be incorporated by reference into this prospectus supplement
and deemed to be part of this prospectus supplement from the date of the filing of such reports and documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may obtain a copy of any or all of the documents referred to above which may have been or may be incorporated by reference into this
prospectus supplement, except for exhibits to those documents (unless the exhibits are specifically incorporated by reference into those
documents) at no cost to you by writing or telephoning us at the following address: Investor Relations, Abeona Therapeutics Inc., 1330
Avenue of the Americas, 33rd Floor, New York, NY 10019, telephone +1 (646) 813-4701.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">PROSPECTUS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">$250,000,000</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">ABEONA
THERAPEUTICS INC.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">Common
Stock</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">Preferred
Stock</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">Warrants</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">Debt
Securities</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus will allow us to issue, from time to time at prices and on terms to be determined at or prior to the time of the offering,
up to $250,000,000 of any combination of the securities described in this prospectus. We may also offer common stock or preferred stock
upon conversion of or exchange for the debt securities or common stock, preferred stock or debt securities upon the exercise
of warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus describes the general terms of these securities and the general manner in which these securities will be offered. We
will provide you with the specific terms of any offering in one or more supplements to this prospectus. We may also authorize
one or more free writing prospectuses to be provided to you in connection with these offerings. The prospectus supplements and
any related free writing prospectus will also describe the specific manner in which these securities will be offered and may also
supplement, update or amend information contained in this document. You should read this prospectus, any prospectus supplement,
and any related free writing prospectus, as well as any documents incorporated by reference into this prospectus or any prospectus
supplement, carefully before you invest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
securities may be sold directly by us to you, through agents designated from time to time or to or through underwriters or dealers.
For additional information on the methods of sale, you should refer to the section entitled &ldquo;Plan of Distribution&rdquo;
in this prospectus and in the applicable prospectus supplement. If any underwriters or agents are involved in the sale of our
securities with respect to which this prospectus is being delivered, the names of such underwriters or agents and any applicable
fees, commissions or discounts and over-allotment options will be set forth in a prospectus supplement. The price to the public
of such securities and the net proceeds that we expect to receive from such sale will also be set forth in a prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on The Nasdaq Capital Market (&ldquo;Nasdaq&rdquo;), under the symbol &ldquo;ABEO.&rdquo; On June 4, 2021,
the last reported sale price of our common stock on Nasdaq was $1.69 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investing
in our securities involves a high degree of risk. Before deciding whether to invest in our securities, you should consider carefully
the risks that we have described on page 4 of this prospectus under the caption &ldquo;Risk Factors.&rdquo; We may include specific
risk factors in supplements to this prospectus and any related free writing prospectus under the caption &ldquo;Risk Factors.&rdquo;
This prospectus may not be used to sell our securities unless accompanied by a prospectus supplement.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
date of this prospectus is October 22, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>TABLE OF CONTENTS<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-transform: uppercase; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>Page</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-transform: uppercase; text-align: left"><A HREF="#g_002"><FONT STYLE="font-family: Times New Roman, Times, Serif">ABOUT THIS PROSPECTUS</FONT></A></TD>
    <TD STYLE="width: 0.5in; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">1</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-transform: uppercase; text-align: left"><A HREF="#g_003"><FONT STYLE="font-family: Times New Roman, Times, Serif">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-transform: uppercase; text-align: left"><A HREF="#g_004"><FONT STYLE="font-family: Times New Roman, Times, Serif">THE COMPANY</FONT></A></TD>
    <TD STYLE="text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">3</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-transform: uppercase; text-align: left"><A HREF="#g_005"><FONT STYLE="font-family: Times New Roman, Times, Serif">RISK FACTORS</FONT></A></TD>
    <TD STYLE="text-transform: uppercase; text-align: center">4</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-transform: uppercase; text-align: left"><A HREF="#g_006"><FONT STYLE="font-family: Times New Roman, Times, Serif">USE OF PROCEEDS</FONT></A></TD>
    <TD STYLE="text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">5</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-transform: uppercase; text-align: left"><A HREF="#g_007"><FONT STYLE="font-family: Times New Roman, Times, Serif">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">6</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-transform: uppercase; text-align: left"><A HREF="#g_008"><FONT STYLE="font-family: Times New Roman, Times, Serif">GENERAL DESCRIPTION OF SECURITIES THAT WE MAY SELL</FONT></A></TD>
    <TD STYLE="text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">8</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-transform: uppercase; text-align: left"><A HREF="#g_009"><FONT STYLE="font-family: Times New Roman, Times, Serif">DESCRIPTION OF OUR COMMON STOCK</FONT></A></TD>
    <TD STYLE="text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">9</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-transform: uppercase; text-align: left"><A HREF="#g_010"><FONT STYLE="font-family: Times New Roman, Times, Serif">DESCRIPTION OF OUR PREFERRED STOCK</FONT></A></TD>
    <TD STYLE="text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">11</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-transform: uppercase; text-align: left"><A HREF="#g_011"><FONT STYLE="font-family: Times New Roman, Times, Serif">DESCRIPTION OF OUR WARRANTS</FONT></A></TD>
    <TD STYLE="text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">12</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-transform: uppercase; text-align: left"><A HREF="#g_012"><FONT STYLE="font-family: Times New Roman, Times, Serif">DESCRIPTION OF OUR DEBT SECURITIES</FONT></A></TD>
    <TD STYLE="text-transform: uppercase; text-align: center">14</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-transform: uppercase; text-align: left"><A HREF="#g_013"><FONT STYLE="font-family: Times New Roman, Times, Serif">WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION BY REFERENCE</FONT></A></TD>
    <TD STYLE="text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">19</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-transform: uppercase; text-align: left"><A HREF="#g_014"><FONT STYLE="font-family: Times New Roman, Times, Serif">LEGAL MATTERS</FONT></A></TD>
    <TD STYLE="text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">20</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-transform: uppercase; text-align: left"><A HREF="#g_015"><FONT STYLE="font-family: Times New Roman, Times, Serif">EXPERTS</FONT></A></TD>
    <TD STYLE="text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">20</FONT></TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 13; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="g_002"></A>ABOUT
THIS PROSPECTUS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus is part of a &ldquo;shelf&rdquo; registration statement. Under this shelf registration process, we may sell, at any time and
from time to time, in one or more offerings, any combination of the securities described in this prospectus. The exhibits to our Registration
Statement contain the full text of certain contracts and other important documents we have summarized in this prospectus. Since these
summaries may not contain all the information that you may find important in deciding whether to purchase the securities we offer, you
should review the full text of these documents. The Registration Statement and the exhibits can be obtained from the Securities and Exchange
Commission (&ldquo;SEC&rdquo;) as indicated under the heading &ldquo;Where You Can Find More Information; Incorporation By Reference.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus only provides you with a general description of the securities we may offer. Each time we sell securities, we will provide
a prospectus supplement that contains specific information about the terms of those securities and the terms of that offering. The prospectus
supplement may also add, update, or change information contained in this prospectus. You should read both this prospectus and any prospectus
supplement together with the additional information described below under the heading &ldquo;Where You Can Find More Information;
Incorporation By Reference.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not authorized any dealer, agent, or other person to give any information or to make any representation other than those
contained or incorporated by reference into this prospectus and any accompanying prospectus supplement. You must not rely upon
any information or representation not contained or incorporated by reference into this prospectus or an accompanying prospectus
supplement. This prospectus and the accompanying prospectus supplement, if any, do not constitute an offer to sell or the solicitation
of an offer to buy any securities other than the registered securities to which they relate, nor do this prospectus and the accompanying
prospectus supplement, if any, constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction
to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. You should not assume that the information
contained in this prospectus and any accompanying prospectus supplement is accurate on any date subsequent to the date set forth
on the front of the document or that any information we have incorporated by reference is correct on any date subsequent to the
date of the document incorporated by reference, even though this prospectus and any accompanying prospectus supplement is delivered
or securities are sold on a later date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">References
in this prospectus to the terms &ldquo;the Company,&rdquo; &ldquo;Abeona,&rdquo; &ldquo;we,&rdquo; &ldquo;our&rdquo; and &ldquo;us&rdquo;
or other similar terms mean Abeona Therapeutics Inc., unless we state otherwise or the context indicates otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="g_003"></A>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus, any prospectus supplement, and the other documents we have filed with the SEC that are incorporated herein by reference
contain forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of
historical facts, regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects,
plans, objectives of management or other financial items are forward-looking statements. The words &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo;
&ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;seek,&rdquo; &ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;plan,&rdquo;
&ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;will,&rdquo; &ldquo;would&rdquo; and similar expressions are intended to
identify forward-looking statements, although not all forward-looking statements contain these identifying words.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not
place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions
and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements
included in this prospectus, particularly as set forth and incorporated by reference into the &ldquo;Risk Factors&rdquo; section
below, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make.
Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures,
collaborations, or investments we may make.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read this prospectus, any supplements to this prospectus and the documents that we incorporate by reference into this prospectus
completely and with the understanding that our actual future results may be materially different from what we expect. We do not
assume any obligation to update any forward-looking statements, except as otherwise required by law. We advise you, however, to
consult any further disclosures we make on related subjects in our future annual reports on Form 10-K, quarterly reports on Form
10-Q and current reports on Form 8-K we file with or furnish to the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="g_004"></A>THE
COMPANY</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Overview</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abeona
Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for life-threatening rare genetic
diseases. Our lead clinical programs consist of (i) EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic
epidermolysis bullosa (&ldquo;RDEB&rdquo;), (ii) ABO-102, an adeno-associated virus (&ldquo;AAV&rdquo;)-based gene therapy for
Sanfilippo syndrome type A (&ldquo;MPS IIIA&rdquo;), and (iii) ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type
B (&ldquo;MPS IIIB&rdquo;). We continue to develop additional AAV-based gene therapies designed to treat ophthalmic and other
diseases, next-generation AAV-based gene therapies using our own novel capsids and capsids from the AIM&trade; capsid library
that we have exclusively licensed from the University of North Carolina at Chapel Hill, and internal AAV vector research programs.
A number of our product candidates are eligible for orphan drug designation, breakthrough therapy designation, or other expedited
review processes in the U.S., Europe, Japan, or other world markets. Our pipeline includes three programs in clinical development&mdash;EB-101,
ABO-101 and ABO-102&mdash;for which we hold several U.S. and European Union (&ldquo;EU&rdquo;) regulatory designations, and a
pipeline of additional earlier stage programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Mission and Strategy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abeona
is at the forefront of gene and cell therapy research and development. We are a fully-integrated company featuring therapies in
clinical development, in-house manufacturing facilities, a robust pipeline, and scientific and clinical leadership. We see our
mission as working to create, develop, manufacture, and deliver gene and cell therapies for people impacted by serious diseases.
We partner with leading academic researchers, patient advocacy organizations and caregivers to develop therapies that address
the underlying cause of a broad spectrum of rare genetic diseases for which no effective treatment options exist today.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our last fiscal year, we have continued to make progress toward fulfilling our goal of harnessing the promise of genetic medicine
to transform the lives of people impacted by serious diseases and redefining the standard of care through gene and cell therapies.
Our strategy to achieve this goal consists of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Advancing
Our Clinical Gene and Cell Therapy Programs and Research and Development with a Focus on Rare and Orphan Diseases.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have three programs in clinical development&mdash;EB-101, ABO-101 and ABO-102&mdash;and a pipeline of additional earlier stage
programs. Through our gene and cell therapy research and development expertise, we believe we are positioned to introduce efficacious
and safe therapeutics to transform the standard of care in devastating diseases and establish our leadership position in the field.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Applying
Novel Next-Generation AIM&trade; Capsid Technology to Develop New In-Vivo Gene Therapies.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are researching and developing next-generation AAV-based gene therapy using our own novel capsids and capsids from the AIM&trade;
capsid library. We plan to continue to develop AAV capsids capable of improved tissue targeting for various indications and potentially
evading immunity to wildtype AAV vectors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Establishing
Leadership Position in Commercial-Scale Gene and Cell Therapy Manufacturing.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
established current Good Manufacturing Practice (&ldquo;cGMP&rdquo;), clinical-scale manufacturing capabilities for gene-corrected
cell therapy and AAV-based gene therapies in our state-of-the-art Cleveland facility. We believe that our platform provides us
with distinct advantages, including flexibility, scale, reliability, and the potential for reduced development risk, reduced cost,
and faster times to market. We have focused on establishing internal Chemistry, Manufacturing and Controls (&ldquo;CMC&rdquo;)
capabilities that drive value for our organization through process development, assay development and manufacturing. We have also
deployed robust quality systems governing all aspects of product lifecycle from preclinical through commercial stage.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Establishing
Additional Gene and Cell Therapy Franchises and Adjacencies through In-Licensing and Strategic Partnerships.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
seek to be the partner of choice in gene therapy treatment and have closely collaborated with leading academic institutions, key
opinion leaders, patient foundations, and industry partners to generate novel intellectual property, accelerate research and development,
and understand the needs of patients and their families.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Maintaining
and Growing Our IP Portfolio.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
strive to have a leading intellectual property portfolio. To that end, we seek patent rights for various aspects of our programs,
including vector engineering and construct design, our production process, and all features of our clinical products including
composition of matter and method of administration and delivery. We expect to continue to expand our intellectual property portfolio
by aggressively seeking patent rights for promising aspects of our product engine and product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
Information</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were incorporated in 1974. On October 24, 2014, we changed our name to PlasmaTech Biopharmaceuticals, Inc., and on June 19, 2015,
we changed our name to Abeona Therapeutics Inc. to reflect our broader rare disease commitment. Our principal executive office
is located at 1330 Avenue of the Americas, 33rd Floor, New York, NY 10019 and our telephone number is (646) 813-4701. Our website
is www.abeonatherapeutics.com. We do not incorporate by reference into this prospectus the information on our website, and you
should not consider it as part of this prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="g_005"></A>RISK
FACTORS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
investment in our securities involves risks and uncertainties. Before making an investment decision, you should carefully consider
these risks as well as other information we include or incorporate by reference in this prospectus. In particular, you should
carefully consider the information under the heading &ldquo;Risk Factors,&rdquo; as well as the factors listed under the heading
&ldquo; Forward-Looking Statements,&rdquo; in each case contained in our Annual Report on Form 10-K for
our most recent fiscal year, in any Quarterly Reports on Form 10-Q that have been filed since our most recent Annual Report on
Form 10-K, and in any other documents that we file (not furnish) with the SEC under the Securities Exchange Act of 1934, as amended
(the &ldquo;Exchange Act&rdquo;), each of which is incorporated by reference in this prospectus. Any of the risks described could
significantly and negatively affect our business, financial condition, results of operations, cash flows and prospects and the
trading price of our securities. You could lose all or part of your investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="g_006"></A>USE
OF PROCEEDS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise specified in a prospectus supplement accompanying this prospectus, the net proceeds from the sale of the securities
to which this prospectus relates will be used to fund continued clinical development of pipeline products, as well as for working
capital and general corporate purposes. General corporate purposes may include repayment of debt, acquisitions, additions to working
capital, capital expenditures, research and development and investments in our subsidiaries. Net proceeds may be temporarily invested
prior to use.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="g_007"></A>PLAN
OF DISTRIBUTION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may sell the offered securities in any of the ways described below or in any combination or any other way set forth in an applicable
prospectus supplement from time to time:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                         or through underwriters or dealers;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">through
                                         one or more agents; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">directly
                                         to purchasers or to a single purchaser.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
distribution of the securities may be effected from time to time in one or more transactions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
                                         a fixed price, or prices, which may be changed from time to time;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
                                         market prices prevailing at the time of sale;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
                                         prices related to such prevailing market prices; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
                                         negotiated prices.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
prospectus supplement will describe the method of distribution of the securities and any applicable restrictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
prospectus supplement with respect to the securities of a particular series will describe the terms of the offering of the securities,
including the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         name or names of any underwriters, dealers or agents and the amounts of securities underwritten
                                         or purchased by each of them;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         public offering price of the securities and the proceeds to us and any discounts, commissions
                                         or concessions allowed or reallowed or paid to dealers; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                         securities exchanges on which the securities may be listed.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
offering price and any discounts or concessions allowed or reallowed or paid to dealers may be changed from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Only
the agents or underwriters named in each prospectus supplement are agents or underwriters in connection with the securities being
offered thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may authorize underwriters, dealers or other persons acting as our agents to solicit offers by certain institutions to purchase
securities from us pursuant to delayed delivery contracts providing for payment and delivery on the date stated in each applicable
prospectus supplement. Each contract will be for an amount not less than, and the aggregate amount of securities sold pursuant
to such contracts shall not be less nor more than, the respective amounts stated in each applicable prospectus supplement. Institutions
with whom the contracts, when authorized, may be made include commercial and savings banks, insurance companies, pension funds,
investment companies, educational and charitable institutions, and other institutions, but shall in all cases be subject to our
approval. Delayed delivery contracts will be subject only to those conditions set forth in each applicable prospectus supplement,
and each prospectus supplement will set forth any commissions we pay for solicitation of these contracts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agents,
underwriters and other third parties described above may be entitled to indemnification by us against certain civil liabilities,
including liabilities under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), or to contribution from
us with respect to payments which the agents, underwriters or other third parties may be required to make in respect thereof.
Agents, underwriters and such other third parties may be customers of, engage in transactions with, or perform services for us
in the ordinary course of business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
or more firms, referred to as &ldquo;remarketing firms,&rdquo; may also offer or sell the securities, if a prospectus supplement
so indicates, in connection with a remarketing arrangement upon their purchase. Remarketing firms will act as principals for their
own accounts or as our agents. These remarketing firms will offer or sell the securities in accordance with the terms of the securities.
Each prospectus supplement will identify and describe any remarketing firm and the terms of its agreement, if any, with us and
will describe the remarketing firm&rsquo;s compensation. Remarketing firms may be deemed to be underwriters in connection with
the securities they remarket. Remarketing firms may be entitled under agreements that may be entered into with us to indemnification
by us against certain civil liabilities, including liabilities under the Securities Act, and may be customers of, engage in transactions
with or perform services for us in the ordinary course of business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
underwriters may use this prospectus and any accompanying prospectus supplement for offers and sales related to market-making
transactions in the securities. These underwriters may act as principal or agent in these transactions, and the sales will be
made at prices related to prevailing market prices at the time of sale.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities we offer may be new issues of securities and may have no established trading market. The securities may or may not
be listed on a securities exchange. Underwriters may make a market in these securities, but will not be obligated to do so and
may discontinue any market making at any time without notice. We can make no assurance as to the liquidity of, or the existence
of trading markets for, any of the securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
persons participating in an offering may engage in overallotment, stabilizing transactions, short covering transactions and penalty
bids in accordance with rules and regulations under the Exchange Act. Overallotment involves sales in excess of the offering size,
which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing
bids do not exceed a specified maximum. Short covering transactions involve purchases of the securities in the open market after
the distribution is completed to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from
a dealer when the securities originally sold by the dealer are purchased in a short covering transaction to cover short positions.
Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters
may discontinue any of the activities at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also may sell any of the securities through agents designated by us from time to time. We will name any agent involved in the
offer or sale of these securities and will list commissions payable by us to these agents in the applicable prospectus supplement.
These agents will be acting on a best efforts basis to solicit purchases for the period of its appointment, unless stated otherwise
in the applicable prospectuses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may sell any of the securities directly to purchasers. In this case, we will not engage underwriters or agents in the offer and
sale of these securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may engage in sales deemed to be &ldquo;at the market offerings&rdquo; as defined in Rule 415 promulgated under the Securities
Act, including sales made directly on or through Nasdaq, the existing trading market for our common stock, sales made to or through
a market maker other than on an exchange or otherwise, in negotiated transactions at market prices prevailing at the time of sale
or at prices related to such prevailing market prices and/or any other method permitted by law. The terms of such &ldquo;at the
market offerings&rdquo; will be set forth in the applicable prospectus supplement. We may engage an agent to act as a sales agent
in such &ldquo;at the market offerings&rdquo; on a best efforts basis using commercially reasonable efforts consistent with normal
trading and sales practices, on mutually agreed terms between such agent and us. We will name any agent involved in such &ldquo;at
the market offerings&rdquo; of securities and will list commissions payable by us to these agents in the applicable prospectus
supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we may enter into derivative transactions with third parties, or sell securities not covered by this prospectus to third
parties in privately negotiated transactions. If the applicable prospectus supplement so indicates, in connection with those derivatives,
the third parties may sell securities covered by this prospectus and the applicable prospectus supplement, including in short
sale transactions. If so, the third party may use securities pledged by us or borrowed from us or others to settle those sales
or to close out any related open borrowings of stock, and may use securities received from us in settlement of those derivatives
to close out any related open borrowings of stock. The third party in such sale transactions will be an underwriter and, if not
identified in this prospectus, will be named in the applicable prospectus supplement (or a post-effective amendment). In addition,
we may otherwise loan or pledge securities to a financial institution or other third party that in turn may sell the securities
short using this prospectus and an applicable prospectus supplement. Such financial institution or other third party may transfer
its economic short position to investors in our securities or in connection with a concurrent offering of other securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
specific terms of any lock-up provisions in respect of any given offering will be described in the applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
compliance with the guidelines of the Financial Industry Regulatory Authority, Inc. (&ldquo;FINRA&rdquo;), the maximum consideration
or discount to be received by any FINRA member or independent broker dealer may not exceed 8% of the aggregate proceeds of the
offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters, dealers and agents may engage in transactions with us, or perform services for us, in the ordinary course of business
for which they receive compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="g_008"></A>GENERAL
DESCRIPTION OF SECURITIES THAT WE MAY SELL</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may offer and sell, at any time and from time to time:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                         of our common stock;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                         of our preferred stock;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
                                         to purchase shares of our common stock, preferred stock and/or debt securities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt
                                         securities consisting of debentures, notes or other evidences of indebtedness; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                         combination of these securities.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
terms of any securities we offer will be determined at the time of sale. We may issue debt securities that are exchangeable for
or convertible into common stock or any of the other securities that may be sold under this prospectus. When particular securities
are offered, a supplement to this prospectus will be filed with the SEC, which will describe the terms of the offering and sale
of the offered securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="g_009"></A>DESCRIPTION
OF OUR COMMON STOCK</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
authorized capital stock consists of 200,000,000 shares of common stock, $0.01 par value per share, and 2,000,000 shares of preferred
stock, $0.01 par value per share, which may be issued in one or more series. The following summary of the terms of our common stock is
subject to and qualified in its entirety by reference to our restated certificate of incorporation (the &ldquo;Certificate of
Incorporation&rdquo;) and amended and restated bylaws (the &ldquo;Bylaws&rdquo;). Please refer to &ldquo;Where You Can Find More
Information; Incorporation By Reference&rdquo; below for directions on obtaining these documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 4, 2021, we had 99,892,667 shares of common stock outstanding and no shares of preferred stock outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and have the
right to vote cumulatively for the election of directors. This means that in the voting at our annual meeting, each stockholder
or his proxy may multiply the number of his shares by the number of directors to be elected, then cast the resulting total number
of votes for a single nominee, or distribute such votes on the ballot among the nominees as desired. Holders of our common stock
are entitled to receive ratably such dividends, if any, as may be declared by our Board of Directors (the &ldquo;Board&rdquo;)
out of funds legally available therefor, subject to any preferential dividend rights for our outstanding preferred stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
our liquidation, dissolution, or winding up, the holders of our common stock are entitled to receive ratably our net assets available
after the payment of all debts and other liabilities and subject to the prior rights of any of our outstanding preferred stock.
Holders of our common stock have no preemptive, subscription, redemption, or conversion rights. The rights, preferences, and privileges
of holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series
of our preferred stock which we may designate and issue in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stockholders may not receive any assets or funds until our creditors have been paid in full and the preferential or participating
rights of our preferred stockholders have been satisfied. If we participate in a corporate merger, consolidation, purchase or
acquisition of property or stock, or other reorganization, any payments or shares of stock allocated to our common stockholders
will be distributed pro rata to holders of our common stock on a per share basis. If we redeem, repurchase, or otherwise acquire
for payment any shares of our common stock, we will treat each share of common stock identically.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue additional shares of our common stock, if authorized by the Board, without the common stockholders&rsquo; approval,
unless required by Delaware law or a stock exchange on which our securities are traded. If we receive the appropriate payment,
shares of our common stock that we issue will be fully paid and nonassessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-Takeover
Provisions</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the provisions of Section 203 of the General Corporation Law of Delaware (&ldquo;DGCL&rdquo;). Section 203 prohibits
certain publicly held Delaware corporations from engaging in a &ldquo;business combination&rdquo; with an &ldquo;interested stockholder,&rdquo;
for a period of three years after the date of the transaction in which the person became an &ldquo;interested stockholder,&rdquo;
unless the business combination is approved in a prescribed manner. A &ldquo;business combination&rdquo; includes mergers, asset
sales and other transactions resulting in a financial benefit to the interested stockholder. Subject to certain exceptions, an
&ldquo;interested stockholder&rdquo; is a person or entity who, together with affiliates and associates, owns (or within the preceding
three years, did own) 15% or more of the corporation&rsquo;s voting stock. The statute contains provisions enabling a corporation
to avoid the statute&rsquo;s restrictions if the stockholders holding a majority of the corporation&rsquo;s voting stock approve
the transaction. Moreover, our Certificate of Incorporation provides that our directors shall be divided into three classes, with
the terms of each class to expire in different years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our Certificate of Incorporation, in order to combat &ldquo;greenmail,&rdquo; provides in general that any direct or
indirect purchase by us of any of our voting stock or rights to acquire voting stock known to be beneficially owned by any person
or group which holds more than five percent of a class of our voting stock and which has owned the securities being purchased
for less than two years must be approved by the affirmative vote of at least two-thirds of the votes entitled to be cast by the
holders of voting stock, subject to certain exceptions. The prohibition of&thinsp; &ldquo;greenmail&rdquo; may tend to discourage
or foreclose certain acquisitions of our securities which might temporarily increase the price of our securities. Discouraging
the acquisition of a large block of our securities by an outside party may also have a potential negative effect on takeovers.
Parties seeking control of us through large acquisitions of our securities will not be able to resort to &ldquo;greenmail&rdquo;
should their bid fail, thus making such a bid less attractive to persons seeking to initiate a takeover effort.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Elimination
of Monetary Liability for Officers and Directors</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation incorporates certain provisions permitted under DGCL relating to the liability of directors. The
provisions eliminate a director&rsquo;s liability for monetary damages for a breach of fiduciary duty, including gross negligence,
except in circumstances involving certain wrongful acts, such as the breach of director&rsquo;s duty of loyalty or acts or omissions
involving intentional misconduct or a knowing violation of law. These provisions do not eliminate a director&rsquo;s duty of care.
Moreover, these provisions do not apply to claims against a director for certain violations of law, including knowing violations
of federal securities law. Our Certificate of Incorporation also contains provisions to indemnify the directors, officers, employees,
or other agents to the fullest extent permitted by DGCL. We believe that these provisions will assist us in attracting and retaining
qualified individuals to serve as directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation also contains provisions to indemnify the directors, officers, employees, or other agents to the
fullest extent permitted by DGCL. These provisions may have the practical effect in certain cases of eliminating the ability of
stockholders to collect monetary damages from directors. We believe that these provisions will assist us in attracting or retaining
qualified individuals to serve as our directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Nasdaq Capital Market</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on Nasdaq under the symbol &ldquo;ABEO.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transfer
Agent and Registrar</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transfer agent and registrar for our common stock is American Stock Transfer &amp; Trust Company, New York, New York.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="g_010"></A>DESCRIPTION
OF OUR PREFERRED STOCK</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board may, without further action by our stockholders, from time to time, direct the issuance of shares of preferred stock in
series and may, at the time of issuance, determine the rights, preferences, and limitations of each series, including voting rights,
dividend rights and redemption and liquidation preferences. Satisfaction of any dividend preferences of outstanding shares of
our preferred stock would reduce the amount of funds available for the payment of dividends on shares of our common stock. Holders
of shares of our preferred stock may be entitled to receive a preference payment in the event of any liquidation, dissolution
or winding-up of our Company before any payment is made to the holders of shares of our common stock. In some circumstances, the
issuance of shares of preferred stock may render more difficult or tend to discourage a merger, tender offer or proxy contest,
the assumption of control by a holder of a large block of our securities or the removal of incumbent management. Upon the affirmative
vote of the Board, without stockholder approval, we may issue shares of preferred stock with voting and conversion rights which
could adversely affect the holders of shares of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we offer a specific class or series of preferred stock under this prospectus, we will describe the terms of the preferred stock
in the prospectus supplement for such offering and will file a copy of the certificate establishing the terms of the preferred
stock with the SEC. To the extent required, this description will include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         title and stated value;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         number of shares offered, the liquidation preference per share and the purchase price;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         dividend rate(s), period(s) and/or payment date(s) or method(s) of calculation for such
                                         dividends;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
                                         dividends will be cumulative or non-cumulative and, if cumulative, the date from which
                                         dividends will accumulate;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         procedures for any auction and remarketing, if any;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         provisions for a sinking fund, if any;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         provisions for redemption, if applicable;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                         listing of the preferred stock on any securities exchange or market;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
                                         the preferred stock will be convertible into our common stock, and, if applicable, the
                                         conversion price (or how it will be calculated), the conversion period and any other
                                         terms of conversion (including any anti-dilution provisions, if any);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
                                         the preferred stock will be exchangeable into debt securities, and, if applicable, the
                                         exchange price (or how it will be calculated), the exchange period and any other terms
                                         of exchange (including any anti-dilution provisions, if any);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">voting
                                         rights, if any, of the preferred stock;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                         discussion of any material U.S. federal income tax considerations applicable to the preferred
                                         stock;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         relative ranking and preferences of the preferred stock as to dividend rights and rights
                                         upon liquidation, dissolution or winding up of the affairs of the Company;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                         material limitations on issuance of any class or series of preferred stock ranking senior
                                         to or on parity with the series of preferred stock as to dividend rights and rights upon
                                         liquidation, dissolution or winding up of the Company; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                         other affirmative, negative, or other covenants or contractual rights which might be
                                         attendant with the specific class or series of preferred stock.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preferred stock offered by this prospectus, when issued, will not have, or be subject to, any preemptive or similar rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transfer
Agent and Registrar</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transfer agent and registrar for any series or class of preferred stock will be set forth in each applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="g_011"></A>DESCRIPTION
OF OUR WARRANTS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
section describes the general terms and provisions of our warrants to acquire our securities that we may issue from time to time.
The applicable prospectus supplement will describe the specific terms of the warrants offered through that prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue warrants for the purchase of our debt securities, common stock or preferred stock or other securities issued by us.
We may issue warrants independently or together with other securities, and they may be attached to or separate from the other
securities. We will file a copy of the warrant and warrant agreement with the SEC each time we issue a series of warrants, and
these warrants and warrant agreements will be incorporated by reference into the Registration Statement of which this prospectus
is a part. A holder of our warrants should refer to the provisions of the applicable warrant agreement and prospectus supplement
for more specific information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
applicable prospectus supplement will contain, where applicable, the following terms of and other information relating to the
warrants:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         specific designation and aggregate number of, and the price at which we will issue, the
                                         warrants;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         currency or currency units in which the offering price, if any, and the exercise price
                                         are payable;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         designation, amount, and terms of the securities purchasable upon exercise of the warrants;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                         applicable, the exercise price for shares of our common stock and the number of shares
                                         of common stock to be received upon exercise of the warrants;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                         applicable, the exercise price for shares of our preferred stock, the number of shares
                                         of preferred stock to be received upon exercise and a description of that class or series
                                         of our preferred stock;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                         applicable, the exercise price for our debt securities, the amount of our debt securities
                                         to be received upon exercise and a description of that series of debt securities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         date on which the right to exercise the warrants will begin and the date on which that
                                         right will expire or, if the warrants may not be continuously exercised throughout that
                                         period, the specific date or dates on which the warrants may be exercised;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
                                         the warrants will be issued in fully registered form or bearer form, in definitive or
                                         global form or in any combination of these forms, although, in any case, the form of
                                         a warrant included in a unit will correspond to the form of the unit and of any security
                                         included in that unit;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                         applicable material U.S. federal income tax consequences;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         identity of the warrant agent for the warrants and of any other depositaries, execution
                                         or paying agents, transfer agents, registrars, or other agents;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         proposed listing, if any, of the warrants or any securities purchasable upon exercise
                                         of the warrants on any securities exchange;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                         applicable, the date from and after which the warrants and the common stock, preferred
                                         stock or debt securities will be separately transferable;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                         applicable, the minimum or maximum amount of the warrants that may be exercised at any
                                         one time;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">information
                                         with respect to book-entry procedures, if any;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                         redemption or call provisions;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
                                         the warrants are to be sold separately or with other securities as parts of units; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                         additional terms of the warrants, including terms, procedures and limitations relating
                                         to the exchange and exercise of the warrants.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
your warrants expire they will become void. All warrants will be issued in registered form. The prospectus supplement may provide
for the adjustment of the exercise price of the warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
may be exercised at the appropriate office of the warrant agent, or any other office indicated in the applicable prospectus supplement.
Before the exercise of warrants, holders will not have any of the rights of holders of the securities purchasable upon exercise
and will not be entitled to payments made to holders of those securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrant agreements may be amended or supplemented without the consent of the holders of the warrants to which it applies to effect
changes that are not inconsistent with the provisions of the warrants and that do not materially and adversely affect the interests
of the holders of the warrants. However, any amendment that materially and adversely alters the rights of the holders of warrants
will not be effective unless the holders of at least a majority of the applicable warrants then outstanding approve the amendment.
Every holder of an outstanding warrant at the time any amendment becomes effective, by continuing to hold the warrant, will be
bound by the applicable warrant agreement as amended. The prospectus supplement applicable to a particular series of warrants
may provide that certain provisions of the warrants, including the securities for which they may be exercisable, the exercise
price and the expiration date, may not be altered without the consent of the holder of each warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transfer
Agent and Registrar</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transfer agent and registrar for any warrants will be set forth in the applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="g_012"></A>DESCRIPTION
OF OUR DEBT SECURITIES</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
section describes the general terms and provisions of the debt securities that we may offer under this prospectus, any of which
may be issued as convertible or exchangeable debt securities. We will set forth the particular terms of the debt securities we
offer in a prospectus supplement. The extent, if any, to which the following general provisions apply to particular debt securities
will be described in the applicable prospectus supplement. The following description of general terms relating to the debt securities
and the indenture under which the debt securities will be issued are summaries only and therefore are not complete. You should
read the indenture and the prospectus supplement regarding any particular issuance of debt securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will issue any debt under an indenture to be entered into between us and the trustee identified in the applicable prospectus supplement.
The terms of the debt securities will include those stated in the indenture and those made part of the indenture by reference
to the Trust Indenture Act of 1939, as amended (the &ldquo;Indenture Act&rdquo;), as in effect on the date of the indenture. We
have filed or will file a copy of the form of indenture as an exhibit to the Registration Statement in which this prospectus is
included. The indenture will be subject to and governed by the terms of the Indenture Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may offer under this prospectus up to an aggregate principal amount of&thinsp;$250,000,000 in debt securities, or if debt securities
are issued at a discount, or in a foreign currency, foreign currency units or composite currency, the principal amount as may
be sold for an initial public offering price of up to $250,000,000. Unless otherwise specified in the applicable prospectus supplement,
the debt securities will represent direct, unsecured obligations of the Company and will rank equally with all of our other unsecured
indebtedness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following statements relating to the debt securities and the indenture are summaries, qualified in their entirety by reference
to the detailed provisions of the indenture and the final form indenture as may be filed with a future prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue the debt securities in one or more series with the same or various maturities, at par, at a premium, or at a discount.
We will describe the particular terms of each series of debt securities in a prospectus supplement relating to that series, which
we will file with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
prospectus supplement will set forth, to the extent required, the following terms of the debt securities in respect of which the
prospectus supplement is delivered:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         title of the series;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         aggregate principal amount;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         issue price or prices, expressed as a percentage of the aggregate principal amount of
                                         the debt securities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                         limit on the aggregate principal amount;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         date or dates on which principal is payable;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         interest rate or rates (which may be fixed or variable) or, if applicable, the method
                                         used to determine such rate or rates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         date or dates from which interest, if any, will be payable and any regular record date
                                         for the interest payable;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         place or places where principal and, if applicable, premium and interest, is payable;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         terms and conditions upon which we may, or the holders may require us to, redeem or repurchase
                                         the debt securities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         denominations in which such debt securities may be issuable, if other than denominations
                                         of $1,000 or any integral multiple of that number;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
                                         the debt securities are to be issuable in the form of certificated securities (as described
                                         below) or global securities (as described below);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         portion of principal amount that will be payable upon declaration of acceleration of
                                         the maturity date if other than the principal amount of the debt securities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         currency of denomination;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         designation of the currency, currencies, or currency units in which payment of principal
                                         and, if applicable, premium and interest, will be made;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                         payments of principal and, if applicable, premium or interest, on the debt securities
                                         are to be made in one or more currencies or currency units other than the currency of
                                         denomination, the manner in which the exchange rate with respect to such payments will
                                         be determined;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                         amounts of principal and, if applicable, premium and interest may be determined by reference
                                         to an index based on a currency or currencies or by reference to a commodity, commodity
                                         index, stock exchange index or financial index, then the manner in which such amounts
                                         will be determined;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         provisions, if any, relating to any collateral provided for such debt securities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                         addition to or change in the covenants and/or the acceleration provisions described in
                                         this prospectus or in the indenture;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                         events of default, if not otherwise described below under &ldquo;Defaults and Notice&rdquo;;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         terms and conditions, if any, for conversion into or exchange for shares of our common
                                         stock or preferred stock;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                         depositaries, interest rate calculation agents, exchange rate calculation agents or other
                                         agents; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         terms and conditions, if any, upon which the debt securities shall be subordinated in
                                         right of payment to other indebtedness of the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue discount debt securities that provide for an amount less than the stated principal amount to be due and payable upon
acceleration of the maturity of such debt securities in accordance with the terms of the indenture. We may also issue debt securities
in bearer form, with or without coupons. If we issue discount debt securities or debt securities in bearer form, we will describe
material U.S. federal income tax considerations and other material special considerations which apply to these debt securities
in the applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue debt securities denominated in or payable in a foreign currency or currencies or a foreign currency unit or units. If
we do, we will describe the restrictions, elections, and general tax considerations relating to the debt securities and the foreign
currency or currencies or foreign currency unit or units in the applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange
and/or Conversion Rights</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue debt securities which can be exchanged for or converted into shares of our common stock or preferred stock. If we do,
we will describe the terms of exchange or conversion in the prospectus supplement relating to these debt securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transfer
and Exchange</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue debt securities that will be represented by either:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;book-entry
                                         securities,&rdquo; which means that there will be one or more global securities registered
                                         in the name of a depositary or a nominee of a depositary; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;certificated
                                         securities,&rdquo; which means that they will be represented by a certificate issued
                                         in definitive registered form.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will specify in the prospectus supplement applicable to a particular offering whether the debt securities offered will be book-entry
or certificated securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificated
Debt Securities</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you hold certificated debt securities issued under an indenture, you may transfer or exchange such debt securities in accordance
with the terms of the indenture. You will not be charged a service charge for any transfer or exchange of certificated debt securities
but may be required to pay an amount sufficient to cover any tax or other governmental charge payable in connection with such
transfer or exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global
Securities</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
debt securities of a series may be issued in the form of one or more global securities that will be deposited with a depositary
or its nominees identified in the prospectus supplement relating to the debt securities. In such a case, one or more global securities
will be issued in a denomination or aggregate denominations equal to the portion of the aggregate principal amount of outstanding
debt securities of the series to be represented by such global security or securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
and until it is exchanged in whole or in part for debt securities in definitive registered form, a global security may not be
registered for transfer or exchange except as a whole by the depositary for such global security to a nominee of the depositary
and except in the circumstances described in the prospectus supplement relating to the debt securities. The specific terms of
the depositary arrangement with respect to a series of debt securities will be described in the prospectus supplement relating
to such series.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
Protection in the Event of Change of Control</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
indenture that governs our debt securities covered by this prospectus may not have any covenant or other provision providing for
a put or increased interest or otherwise that would afford holders of our debt securities additional protection in the event of
a recapitalization transaction, a change of control of the Company or a highly leveraged transaction. If we offer any covenants
or provisions of this type with respect to any debt securities covered by this prospectus, we will describe them in the applicable
prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Covenants</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated in this prospectus or the applicable prospectus supplement, our debt securities may not have the benefit of
any covenant that limits or restricts our business or operations, the pledging of our assets or the incurrence by us of indebtedness.
We will describe in the applicable prospectus supplement any material covenants in respect of a series of debt securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidation,
Merger, and Sale of Assets</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may agree in any indenture that governs the debt securities of any series covered by this prospectus that we will not consolidate
with or merge into any other person or convey, transfer, sell or lease our properties and assets substantially as an entirety
to any person, unless such person and such proposed transaction meets various criteria, which we will describe in detail in the
applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Defaults
and Notice</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
debt securities of any series will contain events of default to be specified in the applicable prospectus supplement, which may
include, without limitation:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
                                         to pay the principal of, or premium or make-whole amount, if any, on any debt security
                                         of such series when due and payable (whether at maturity, by call for redemption, through
                                         any mandatory sinking fund, by redemption at the option of the holder, by declaration
                                         or acceleration or otherwise);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
                                         to make a payment of any interest on any debt security of such series when due;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         failure to perform or observe any other covenants or agreements in the indenture with
                                         respect to the debt securities of such series;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain
                                         events relating to our bankruptcy, insolvency, or reorganization; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain
                                         cross defaults, if and as applicable.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an event of default with respect to debt securities of any series shall occur and be continuing, we may agree that the trustee
or the holders of at least 25% in aggregate principal amount of the then outstanding debt securities of such series may declare
the principal amount (or, if the debt securities of such series are issued at an original issue discount, such portion of the
principal amount as may be specified in the terms of the debt securities of such series) of all debt securities of such series
or such other amount or amounts as the debt securities or supplemental indenture with respect to such series may provide, to be
due and payable immediately. Any provisions pertaining to events of default and any remedies associated therewith will be described
in the applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
indenture that governs our debt securities covered by this prospectus may require that the trustee under such indenture shall,
within 90 days after the occurrence of a default, give to holders of debt securities of any series notice of all uncured defaults
with respect to such series known to it. However, in the case of a default that results from the failure to make any payment of
the principal of, premium or make-whole amount, if any, or interest on the debt securities of any series, or in the payment of
any mandatory sinking fund installment with respect to debt securities of such series, if any, the trustee may withhold such notice
if it in good faith determines that the withholding of such notice is in the interest of the holders of debt securities of such
series. Any terms and provisions relating to the foregoing types of provisions will be described in further detail in the applicable
prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
indenture that governs our debt securities covered by this prospectus will contain a provision entitling the trustee to be indemnified
by holders of debt securities before proceeding to exercise any trust or power under the indenture at the request of such holders.
Any such indenture may provide that the holders of at least a majority in aggregate principal amount of the then outstanding debt
securities of any series may direct the time, method, and place of conducting any proceedings for any remedy available to the
trustee, or of exercising any trust or power conferred upon the trustee with respect to the debt securities of such series. However,
the trustee under any such indenture may decline to follow any such direction if, among other reasons, the trustee determines
in good faith that the actions or proceedings as directed may not lawfully be taken, would involve the trustee in personal liability
or would be unduly prejudicial to the holders of the debt securities of such series not joining in such direction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
indenture that governs our debt securities covered by this prospectus may endow the holders of such debt securities to institute
a proceeding with respect to such indenture, subject to certain conditions, which will be specified in the applicable prospectus
supplement and which may include, that the holders of at least a majority in aggregate principal amount of the debt securities
of such series then outstanding make a written request upon the trustee to exercise its power under the indenture, indemnify the
trustee and afford the trustee reasonable opportunity to act. Even so, such holders may have an absolute right to receipt of the
principal of, premium or make-whole amount, if any, and interest when due, to require conversion or exchange of debt securities
if such indenture provides for convertibility or exchangeability at the option of the holder and to institute suit for the enforcement
of such rights. Any terms and provisions relating to the foregoing types of provisions will be described in further detail in
the applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Modification
of the Indenture</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
and the trustee may modify any indenture that governs our debt securities of any series covered by this prospectus with or without
the consent of the holders of such debt securities, under certain circumstances to be described in a prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Defeasance;
Satisfaction and Discharge</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
prospectus supplement will outline the conditions under which we may elect to have certain of our obligations under the indenture
discharged and under which the indenture obligations will be deemed to be satisfied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regarding
the Trustee</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will identify the trustee and any relationship that we may have with such trustee, with respect to any series of debt securities,
in the prospectus supplement relating to the applicable debt securities. You should note that if the trustee becomes a creditor
of the Company, the indenture and the Indenture Act limit the rights of the trustee to obtain payment of claims in certain cases,
or to realize on certain property received in respect of any such claim, as security or otherwise. The trustee and its affiliates
may engage in, and will be permitted to continue to engage in, other transactions with us and our affiliates. If, however, the
trustee acquires any &ldquo;conflicting interest&rdquo; within the meaning of the Indenture Act, it must eliminate such conflict
or resign.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governing
Law</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
law governing the indenture and the debt securities will be identified in the prospectus supplement relating to the applicable
indenture and debt securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="g_013"></A>WHERE
YOU CAN FIND MORE INFORMATION; INCORPORATION BY REFERENCE</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
file annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains a website at
www.sec.gov that contains reports, statements, and other information about issuers, such as us, who file electronically with the
SEC. We maintain a website at www.abeonatherapeutics.com. However, the information on our website is not incorporated by reference
into this prospectus and any prospectus supplement and you should not consider it a part of this prospectus or any accompanying
prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC allows us to &ldquo;incorporate by reference&rdquo; into this prospectus the information in other documents that we file with
it. This means that we can disclose important information to you by referring you to those documents. The information incorporated
by reference is considered to be a part of this prospectus, and information in documents that we file later with the SEC will
automatically update and supersede information contained in documents filed earlier with the SEC or contained in this prospectus.
We incorporate by reference into this prospectus the documents listed below; provided, however, that we are not incorporating,
in each case, any documents or information deemed to have been furnished and not filed in accordance with SEC rules:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                         Annual Report on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/318306/000149315221006705/form10-k.htm" STYLE="-sec-extract: exhibit">Form 10-K</A> for the year ended December 31, 2020;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                         Quarterly Report on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/318306/000149315221011822/form10-q.htm" STYLE="-sec-extract: exhibit">Form 10-Q</A> for the quarter ended March 31, 2021;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            Current Reports on Form 8-K or 8-K/A filed on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/318306/000149315221002234/form8-k.htm" STYLE="-sec-extract: exhibit">February
                                            1, 2021</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/318306/000149315221006620/form8-k.htm" STYLE="-sec-extract: exhibit">March
                                            23, 2021</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/318306/000149315221007196/form8-k.htm" STYLE="-sec-extract: exhibit">March
                                            30, 2021</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/318306/000149315221009122/form8-k.htm" STYLE="-sec-extract: exhibit">April
                                            19, 2021</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/318306/000149315221013234/form8-k.htm" STYLE="-sec-extract: exhibit">May
                                            28, 2021</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/318306/000149315221013235/form8-ka.htm" STYLE="-sec-extract: exhibit">May
                                            28, 2021</A> and <A HREF="https://www.sec.gov/Archives/edgar/data/318306/000149315221029401/form8-k.htm" STYLE="-sec-extract: exhibit">November 19, 2021</A>; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         description of our common stock, par value $0.01 per share contained in our Registration
                                         Statement on <A HREF="https://www.sec.gov/Archives/edgar/data/318306/000114420414065030/v393203_8a12b.htm" STYLE="-sec-extract: exhibit">Form 8-A</A>, dated and filed with the SEC on November 4, 2014, as updated by
                                         <A HREF="https://www.sec.gov/Archives/edgar/data/318306/000149315220004015/ex4-4.htm" STYLE="-sec-extract: exhibit">Exhibit 4.4</A> to our Form 10-K for the fiscal year ended December 31, 2019, and including
                                         any amendments or reports filed with the SEC for the purpose of updating such description.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
reports and other documents we subsequently file pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the
termination of this offering, including all such documents we may file with the SEC after the date of this initial registration
statement and prior to the effectiveness of this registration statement, but excluding any information furnished to and not filed
with, the SEC, will also be incorporated by reference into this prospectus and deemed to be part of this prospectus from the date
of the filing of such reports and documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may obtain a copy of any or all of the documents referred to above which may have been or may be incorporated by reference into
this prospectus, except for exhibits to those documents (unless the exhibits are specifically incorporated by reference into those
documents) at no cost to you by contacting us at the following address and telephone number: Investor Relations, Abeona Therapeutics
Inc., 1330 Avenue of the Americas, 33<SUP>rd</SUP> Floor, New York, NY 10019, telephone (646) 813-4701.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="g_014"></A>LEGAL
MATTERS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise specified in the prospectus supplement accompanying this prospectus, Morgan, Lewis &amp; Bockius LLP will provide opinions
regarding certain legal matters. Certain partners and attorneys of Morgan, Lewis &amp; Bockius LLP hold shares of our common stock.
Additional legal matters may be passed upon for us or any underwriters, dealers, or agents by counsel that we will name in the
applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="g_015"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXPERTS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements incorporated by reference from the Company&rsquo;s Annual Report on Form 10-K for the fiscal
year ended December 31, 2020 have been audited by Whitley Penn LLP, an independent registered public accounting firm, as stated
in their report, which is incorporated by reference into this prospectus. Such financial statements have been so incorporated
in reliance upon the report of such firm given upon their authority as experts in accounting and auditing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>$124,601,795</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="form424b5_01.jpg" ALT="" STYLE="height: 111px; width: 350px"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMMON
STOCK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 40%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSPECTUS
SUPPLEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 40%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 16pt"><B>Jefferies
LLC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
19, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; text-indent: 4.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>form424b5_01.jpg
<TEXT>
begin 644 form424b5_01.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!/0/H P$1  (1 0,1 ?_$ 0\  0 " 04! 0$
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MM-1U-QBBLL)#4R168\-DI"7A\8.C1&4XA,0U)N-%*/_:  P# 0 "$0,1 #\
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MH!+26ZFFG%I!%1Q63=8>LJ2B)1$HBX7DBS$,C8]OK'SJ1=Q#:^+0N2T7$JP
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MC%IF*BH%HU1* $*3S4^GT:<:E7$=0=BS-98V%S'!%& UK7,="QK1P !<UL8
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M1;J^UI9-P-GA=H=VVXX(X(9"X+DC8K*"4<IKZCGV&>OB;<-O)$>K5JV44 0
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M$2B)1$HB41*(OYK$,JDJF54Z!E$SD*LET>8B8Y1*"J?F$43ZTQ'4.HI@U#B
MA7!%00#0D<UPX$M(!H2.?<J6&;=J6X3#-Y7'#7EC.^7C5I*OQ:WK'V]*S5L7
M$S%TK[/-M;CC6[R-ZI)(06.DLH1RD8XD5(4P"%4DSFT=PX:\EBOK:<L:\_;
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M W2Y!=PB4ANE ")=) Q7<?2OK[OR\&:W';.FN"TZ&ON+9@C:370R(2TB'>"
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MF0;J"DO&N;C2496NM(ME"F*LB@]6.@<HD5 AP$M2YMWH'U+W)8LR,%FRVM)
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M=C+6B<P.+$N6:?(QT3$Y3MB9LI%\\<J)HMD$[B<H.K005<KJ@1,BTBF<YN
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MTXD "C2221RH*N(!Q'>F],1L7#_AC+B1T;I!&QD8!?)(X.<&BI#1P:XESB
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M1/I4$A@Q_=7E>VJS;UU+M:2]_*!D1="V65CF/<WVO#<!&T_; "QIU -<0XU
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MCY7ZO#-OH_='OI36[E2M>-:"DX>7G?6Z=[1Y9VYKIUR;8VPCJR-NGQ/E&O\
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M*IF[N^HNV=)^5L8L$"(- 3*NQ0>$<'=E(86IAM7Y:KSIO:37?Y2NM8]UF0>
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MSG"71/359U8]*(E$2B)1$HB41*(O.&[@WX=6[X1Y_OC,N?!_TTEO?K;'TO\
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M=&@.)YM^A<>WV -/SWQFKH=']Z;TW=!='=-IX=M$&>%/X3X?$)+M3-+N#M(
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MCL+=SV4+SK=#)&Q[*N ]L1SL>&EP ]IH!< *D@*/]Q]/]@=0]-_F+:*[E:-
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MLX&ARV,!'_BH/LUNS+/F"I(2!'9IQ,_%0I3D!ED:SW0G(<0*0Y 0F5.HIC&
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MJ9;>=H'.L;A\(7WCRF,F($5Q XGE21A^ KDQ3%.4#$,4Q1#4#%$#%$/2 AJ
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MG%^V-SJ%63$%$RB'B;PVMCMZ;<NMM96HM+E@&IOQF.:X/8]OI8]K74Y.II/
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M'-@?4-8R/4&RZ2 1),'4<X_&BCAI4 *<RJX*PR41*(E$2B)1$HBT$0* F,(
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MN//9!N&WHRVM)I*Z+AA<R*M31DK7EX9PH/&\0-+JDQQ-XJQZ @8 ,40$! !
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MQM/"E"UA:'-X\6N!;7LJ I3\(=_G>SCF0BD,I!86>K7;K)DE6]Q6ZQLN[W+
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M9=F*BV;)\3&$3'$B9#J%]_;&V<SN_-0X' Q&;(3'@.36M'QGO=R:QHXN<?4
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MAX8BW2F60O._[F=F;(KB@43)H'<+/W1$Q!NBL8.FISW)N[9O3?$LER\T%E9
M$10QM&MYYZ8H8Q4BO,AH8VH+W-!JH5V_M7>/4?+F+'1SWEX\@R2O=5K&U#=<
MDKSI;0#@"[4_26QASFZ5;X[>79UPYL[389%R8I$YHW!':Z#<;V/\VQ;".J*2
MBC;'D#*("H:13,GT#-O$P?G)J"";(BBJ1Z*]4^O6>WV7XG#>)C]KZOB!U)IJ
M5XS/::!IY^"PEE?CND(:1=OIAT,PFQ]&6R^B]W-I(U4)AAU4KX37 :GT&GQG
MM#J5$;(@^0.F5J 5.Z41*(E$2B)1$HB410(]^?>8_P &X%@MO>/;D4A\E9\.
MY^<J\8Z5;S$'AV+%1&=43<-5$W,<I>LUY48DI\5=BE(IAQ+J%F?+3L"/<>Y9
M-TY2$28C&T\/4 6ONG4+>!%'>$RKR/G7NB=Z#6_S&;\=M[;L>VL9/X>7OS60
M-)UMMAJ!XCXHDD ;4U#V,E92A)%+/D'AZ ^ ?1[E;!> ]2H1[;G<>+W'M/;7
M]7-7<>RGV]7^UC%,AG#+D U9YSS/&QRD<P<ID6E<=8N61;2<9;:YS$ZXVX+G
M>&(^ET"FZD@19MU *JW5+6N_S"]4H]Y9INV\'*YVW<>]P<0?9GN 2USQV.9&
M*LC=VETC@2US2M@70/IF_:.'.XLQ&T9V^C;H!'M0V[@U^DU&IKY'4=(WL:R)
MI#7AX4Y-5Q5A4HB41=;9BQ3:.<L5Y P_?K,7UH9'M68M.=13\L'*+26:*-RR
M$>JH10K:5BG!B.FBW2(H.44U XE"O7P&;OMN9JUSV-=IOK29LC*\B6FNEW>U
MPJUP[6DCM7E9S$6F?P]SA+ZOR2ZA?&ZG,!P(U-K4!S31S33@X KSI-VNU?)>
MSC-USX1R>W14DX<$I2W;A9 /R1>MF2*[E. NV(ZO6(UDBLU"*HF'K:/$5FY]
M3)&$=K.Q]YXG?NW8=Q8<GP9*M>QWQHI6TUQ/]+:@U'!S2UXX."U<;VV=E=C;
M@EP&6#3<, <US:ADD;OBR,!J=#B#0%Q+2',)+F.IESVBMYC[:3NNM-K<5RJ1
M>$\ONF]A929O72Q(*.4DA%"TKZ60,H5DR=6M<*B .'AB]2<0X>%Y"&F#=<]@
M1[XV5.^TA\3<-BTS6Y &MVGC)"#2I$C*Z65XRB,]BSCHEOU^S-X0,O)_#V_=
MUBN-1.AH(.F0BNEICDTDO(.F/Q!P#RX7Z^?$.(#R&M9"V2)1$HB41*(E$7G"
M]P;\.G=]_C&9<^M\]);W]*VR=,/\.<'_ '3:?<(UJLZD?G[F?[UO?ZW,NBX;
M+M\6[BF]L-PDRXBK(R-=5G7;>S)DNNU4N)S83"YV=M1DH=%4A'<&Q6NUR[,U
M4 R1WB2"PAUH)B&1W.#QMUF;?/7,8?D+6&6*(N (8)C&9"VH]E[O":W4#4,U
M-Y/<#C]KF<G;8N;"6TA;C[J6*21K=0<]\0>V,.(=1S&^(\AA:1XFF0$.C81-
MILO["F9\U,[2R/N,NEKAO%EPQ47<;.V(!=K-Y;GH:79HR,<4Z2C=U;-C>V,G
M"9Q,\,^?-Q$4UF*:@& M>.H'F8V_MZ6?$[5A=D,S$]T9D>"RV8]ITNXU$DM"
M"/8T-=S;*12M@MB>6_/9Z&#)[FF%ABYHP\,;1]R6N%6T:08XR11WVS66_%?"
M34-G>QWV4.W5C]H1%QA5[D!\4" :7R)?5XS;M7H#B)X^-F(2W"]9M1-T,2 (
MCIP*  %:\KYA>JN3?5E^RUB^A@AB:!^V>U\G^FK%8SH#TQQH#GV<MS. !JEG
ME%:=[(G115->)\.O9R  R5A^WEL4@DDD6.T7;TH5$  AY7%=H3R_ 0$!4=3D
M7(N5AU#F<YAK$I^JO4FX<7/SN4!/T%Q(P>\QS0/<"RJ/I;TXC:&_@3&/ _XD
M$<A]TR!Q/NKE">R/9BD7H3VC[8REU$=/N#8L'B(ZB.HVJ(C72=U&Z@N-3G<S
M7[]N?XQ=EO3?IVP4;@<*!]Y6W\4OZ?O*-FG\$G;)^T+BO_LI7'Z1.H'X]S/]
M-N?XU?K]'/3W\0X;^A6W\4N.R_;_ -C<X@+9]M$VY$3$#!U1N'[%A7  ;77I
M=PT(P=$'CS X"'A7;@ZH]2+=VJ/.Y4GZ:ZF>/>>YP^8NJ_I=TX>*#!8IGICM
MHHS[\;6GYJPHSSV+]BV6827"PK0F,#7HZ;*C%7/84[.2,,RD= %LM(6+<<M(
M0#V-*<-%6[3Y.44((@19,VAPD+;/F0ZCX2YC_"D\>2Q[3[4<K&,>6]NF:-K7
MAW<YXD /-I'!8'N3R[]/\S;RG&1RX_(O'LR,>^1@<.58I7N;H^B;$8G$<G@T
M(JH[Y.W1GO87-P2>4!MRY+'O.2F6%C9"M!^JO%3:D,1JY792L2]2;3%LS@,7
MJ2HMER*(*:*@W<.015.6Z?3GJOMGJ7;2'#^+%D;=C#-#*VCF:Z@%K@2V1FH$
M:FFH]DO:PN 5.NH?2O<G3F:-V5$<N.G>\12Q.+FG2>3P6M<QY:6NTD4J7!CI
M PN/7VR7=C?FSK<%8>6+3GI9E;;>X(AEDVV6KAP:+O7'SAZFA<L/)Q952M)!
MXC%KK+1RBA3&:/R)+$T$H@/J=0]DXW?FU[K"WL3'71B>;=Y U13@5C>UU*@:
M@T/ IJ95IX%>9T\WED=E;GM<K9RR,M/&C;,P:BV2'40]CF@@.]ES]%:Z'D2-
M&IH7HX0LS%7'#Q-PP3]M*0D[&,)F'DV:@*M)&*E&J3V/?M50X*-GC1<BA#>)
M3 -:H+FWGM+B2TN6EES$]S'M/ M<TD.:?2"""MI5M<P7EO'=VK@^VE8U['#B
M'-< YKAZ"""/0MSKXK[)1$HBJ!]_/?7]T*_6FS/'4HN%H8ME6L[F-XW,9)"X
M<C^Q%6A+4*HF?5Y$V3&R(K.2&^UJ2S@ ,3S&"9ZO;Y9>F_X*QCM_95@^7WK"
MRU!XF."OM24['S.% >8B:*&DK@J/^9'J,<ED1L?%2.%C:/#K@M) DGX^P:4U
M,A!Y5+3*75:'0L<H),#8!RUN8R5"XDPK:#V]+WG$G3E*/;+-63*/C&"8*R,U
M.2\@NUBX6&8$,4%'#E5,@J'(D3J6523/9/<NY\)M#$29S<-PVWQT= 7&I+G'
M@UC&MJY[W'DUH)H"XT:UQ%=-M[:S.[,M%A<#"Z>^E-*#@&@"KGO=R8QH!)<X
M@5HWBYS6FT'MB^CM8Q@&</<6ZW)DWD"X!3;NW^.L;*J6I9+-<R8&6BI&[5DU
M+NN1!-0P@*[,(,3" : )=>JG&\/-3E[F22UV59QVUMQ GN/MDIX\'-B!$<9I
MV/,P[_1;S:/E@Q=M&RYWC=NN)^!,-O[#!5M"Q\S@9'C420Z-MNX4 J:$NEJL
MGMD[ K :%906T[#;Y,H$^W7G:Z61GHBF4"@8TAD%6YWHB(!Q^V>L/.H0R/6'
MJ?DY/%N,W?L<?^"_Y./>@$8^8IGL.D'3/'PBWBPUG+$/^.TW)]^X=*?FKM=O
MLTV@- (#7:GMM; F42$\C!N,$N@H\RE$EKE$ 'Q]->&_?^_)"3)F\NXGOO+@
M_P#>+W8=A['M@!;X;%, %!IM+<4'N1K]?[T+:;_!?V[_ +2F-?\ LS7S_+K>
M_P".<K_2[C^,78_([:/XJQO]&A^P7\%]G.T5R7I<[5]N#@H:@!5\'XR5* &^
M,&BEL&#CIQK],W[OJ,U9FLL#Z+RX'_>+Y2[(V7.W3/A\6]O<ZU@(^;&NL;R[
M;&PF_&AF4[M,PBT2,)A%:T;)C<?OM3EZ1TDK"+;4B&@<OMN@#Q#C7M6'5WJ;
MC9/$M\YD'.[I93./K9_$;\Q>'>=).FM[$87X6PB8>?@1BW/'Z:W\-WS5$?NC
M^CO8KN-C,7)M.R)-XYN0J3AVPQQD-TO=EAOURD,9&*CKI$GSQME-4P  +O#3
MF@CQ*!1U+..S?-3F;61EIO:UCNK4D!T\ $<P%>+G1?N4E/H6>#[O(PKN_P L
M&)N8W7.S+I]M< 5$$]9(S0<&ME'VQE74)=*+AQXBHJ"VK7F_!N4]N62;@Q)F
M2TGUF7W;9T1?Q3Q1LY0<,W:7G,):)DV*SF-F8>11'J0=-E5$3^L77K*<I;F;
M<W)A=V8B+.8"=MQCI1[+A4$$<"US2 YKFG@6N ([N(K4'<>W,QM3*RX;.0NA
MOXCQ!X@BE0YKAP<UP(+2.!!5A#L&;]"VS<"^R/)<DY/$WE)R%PX)E72BJR,3
M<A8YS(W58*ZJRIB,8R<:1GM\84I2IED0=)CU*.T@JKGF:Z9_++4=0\0P">W8
MUEXT4!='J#8Y@*<7,+M$G,F,L/ 1N5F?+AU*-M=?D%EWN-O.\NM'$$Z)*.?)
M&YU31D@%65  E!;J<Z9@%M&J/JZ:41*(N/7==5OV):MRWM=DDA#6O9\!,71<
M<NZZO9HN"@(]Q*RT@OT%,<4F;!JHH8"@)A O !&NW86-UD[Z'&V+#)>W$K(X
MVCFY[W!K6CTEQ 73R%_:8JPGR>0>(K&VB?+(\\FLC:7/<?0&@E><#N\W/7]N
MVSQ?V8;XGIF19S=Q2XV/ 2#M8\?9%C ]4);5K0D<*RC*+081"2(.?( !=N_-
M<*B=54YS;9-B[/QFQ]MVN"QT4;'QPM\5[0 Z66GVR1[J5<7.)IJ^*VC&T:UH
M&K/?6[LCO'<=UF+Z69\$D[S$Q[JB..M&1M:'%C UK6BC.#B"]Q<]SWNY3L]V
M*[A-\-U3=M8/@8I1C::<6M>=YW7+?(=GVFC,K.D8L)-\DVD))V\D/8'!D6K%
MH[='(@H?RP(0Q@Z._.I&U^G5E'=[BE>))RX111MURR:0"[2TEK0&U%7/<UH)
M U5(7;V+TYW/U"NI;;;[&%D#09))':(F:JAH<X->074- UCG4#G!I#2K5NWS
ML&[-,81T._R\6[<_7H@W05EE+AG'UKV+\I>27V@(BT[47BWHQI''4)$Y&0?F
M,&G7XEJEFZ?,WOW,321X'P,9CR2&Z&"6;37AJDD#FZJ<RR-E.SO5QML>6[9&
M)A9)G739&_ :75<880X#CH;$6RZ2ZII)-)7U<%(+!]O;8O;S8K6.VB[>5$R!
MT@>7Q19UQ.M--/6>W!%2CTXZ!S%01J+[CJIU)N7ZY,[E ?I+F6,>]&YH^8I*
MCZ6].(VAIP>+D [9+>.4_72->?FKE/[R?9H' -I&V30/_ 7%?_92NE^D3J!^
M/<S_ $VY_C5VOT<]/>7X!PW]"MOXI:&V3;,S%$IMI&V02F 2B'W!<5\0$-!#
M^I3Q"N1U%Z@CB,[F?Z;<_P 8AZ<=/"*' X:A_P#!6W\4ME>;!]C[XIRN-H6V
ML .7I,+?"N/&9].D2>JHSM]!0@@!N E$! >/, KL,ZG]1XR"W/9<T[[N=W^L
M\KX'IATX^=P.(:3]#:0-/OM8"NDKT[1/;KOAHLV?[9[3@U50$2/K*F+NLMVV
M4'711'YMW!'-#"01U JB2B?I*-9#CNNG57&O#XLO-*.Z5D4H/U\;G#U@@^E>
M%D>B/3')LT2XQL9!J#%+/%0^ID@:1Z'-+3V@J$K>C]'UNBU4I2_-FETK7C;S
M&-<2#[$.09 @7PFHS;J.%DK*NMLQ;Q5RF=B3I08R";%P00T!TY.8"A8?I]YH
M;*]='C-_0BWNW/#1<P@^"02 #+&7%\=.;GL+VGZ!@"@+?OEGO+429'9$_CVS
M8RXV\I FJT.<1&]K6QR:N :UPC<VG%\A=45GSD,F8Z2A#IJ$,=-1-0ADU"'*
M82J)J)G #D.0X"!BB&H"&@@%6[!#A44(*J80Z-U*T>.T?"*>^"%;=[ V^=I=
M5HR.R[(\Y*NKWM4\S=V''\N\7?(REA%19KSMC-7#I51=N[M!\*SYHAKY9HYR
MH1,$R,]#4=\SG3A]E?-Z@8F-@Q\P;'=-: "V:I#)B .(D%&./,/:TFIDX78\
MMO41E[8'8>4>3?05=:DDG5$!5T/$\XZ%[ * LU"@\.K[+=5$5KTHB4114][$
M->VIN&_F^)_W9L?U-GEW_P 7,9]1=_U.=0EYB./2>_\ OFP_K]LJ#*@:D4 /
MC&(8 Y\S (!X<.(ULR/$<%KHA<V.9KW\@X'YJDUW59CR/W'=PV&L6X+MBY;W
M86'BZPL-XCM!DV.W=RB\!;3%>^KP?-GKA*/A$9.>3<'6?.CMD4(=@T,Z,GY1
MA+$6S,!B>E&V<AF-QS0V\ES>SW=S*34-#Y'"&,$"KM+"T!K=1=*]X8':@#*>
M[<[ENJ&=QV'V_%-<1VME#:VT0;I<2V-OBN(<: O>USBYQ:&Q-89-(C>X2W;3
M_H[C<S6(NW>'DAT5VITNG&(,5KHI)-2^L)&5Q9'7*X,Y5,'3YZ,4T2*0=02?
M*!H>H,WOYJ7:WV.P[0%@X"ZN*\?2R 4IVT,C^/#5&.2G#9GEA#=%YO:Z&KG\
MGM^-.)^-,[V:$4!:R,D<:2FHI,U8':Q[?6-VY&\'M8QA+F*F1,[F_H][DQTJ
M)1U%4ZF0G]RE(J<W$13*0/   .%0#E.M/5'+/UW&9NX^/* MMP/1]H;&??)]
M]3GC.C73/%1>##B+:5AY^.7W-?<G=(!Z@ *<*4X+NEOLPV>-"D*UVH;:VY4M
M!3!'!>+T^@0Y"426L @;ASYUCS^H._9"3)F\NXGOO+@_]XLAAV!L2V ;;X7$
ML Y:;.W'P1K]9]GVTI4HD5VN;=%"&TZB'PEC0Y1T'4-2FMD0'0>-?,;[WPTU
M&9RH/WW<?QB[#MF;/>W2_$XTM[C:P$?ZBXM.;"MD=Q-UFTKM(VY'*ND9(ZS'
M#E@Q#T"' 0$4I"(@F+]!0 -P.10IRCQ 0&N];=3>HMHX.ASF6X&M'74SV^ZU
M[W-(]!%%YL_33IY<DNDP>*#R*:FVL+'?7,8UP]8-5&[N4[!FT;*$!).<$?+>
MWJ_^+B,=,I:>O6PW3@ ,8S.9M:Y9AY(-6KHVA04CGS46P^L"2I0%(TL[2\S6
M^</=,9N7P\IC.3@6LAF [VOC:&DCM#V.U<M33[0BS=7EMV7E;5YVX9<=D2[4
M"7OGB)[0X2N=(T'LT2!K#Q\-X&DU0]W6SC->R?)J6+\TQD61])119^V;FMEX
MYE;0N^$%TLS._@9-VPC71E&CI$4W+5PW0=-C"05$P(HD=2[&Q=_;>ZA8@YC;
M[WF-C]$D<@#98WT!H]H<X<006N:YS7<:$D$"F>]]A9_8&5&*SK&:W,#V/C)?
M&]I)'L.+6$T(((+6NX5+0"%^W9#NNNC9EN-L+-L #U_#1+_Y+R!:[1R=(EWV
M!+?SG<D*9(5DFZ[])HJ+N.%8121DV[=0P"!1 ?GU%V39;^VI<[>NM+9WLU0R
M$<8IF\8WUH3IK[+P.+HRYHXFJ^O3S>E_L3<]OF[,N="UVF6,'A)$X@/90D#4
MX?$<2 UX:XU#:'T6+"OBVLF6/9^1;,D22]HWW;$'=]LRB93)E?P5QQC:6BG0
MI' %$3K,G9!,F8 .F;4I@ 0$*U493&WF&R5QB<@SP[^VF?%(WN?&XM<*]O$&
MA' CB%M"Q63LLUC+?,8Y_B6%U"R6-W+4R1H<TTY@T(J#Q!X'BN6UT%WTHB41
M4Z_I&&7G<_N,Q!A=G+/%(7'.+_G;*1)%U21R5V7[.R2/G+M0."*\@WMJW&9D
MU3%$4TG9BE$.LX5?3RI8%EKM2^W!(QHN+N\\-KJ>T8H6-Y'L:9'O% >);4\@
MJ-^:3<#KC<EEMZ)S_!MK7Q'\?9\25QX4K\81M:22.3Q0\U!7A/#]Y[@,LV!A
M?'B+)Q>>1[B9VU EDW1F48W<.NM5=_)O$T7*S:,BV*"KIR=-)54J")A(F<VA
M1LCN'/8_;&$N<_E2X6%I$9'Z15Q Y!HJ 7.-&M!(!)%2!Q5=MNX#(;HS5O@<
M4&NOKEX8W4X-:*\W.=V-:*N- 30<&DT!N/[8^POM#Q+;[)UG)I*;B,A+M$#2
MSJ;DI>V;"C'PE SA&VK4MR1CG3AJ0YA3\V5=OC+%*!P30$>@M"-X>9??.;N7
M1[<+,7BP3I#6LDF<.PR22-<T'MI&UE.1<[FKS;3\N&RL-;MDW!XF1R5 3[;X
MH6NIQT-B<Q[AV'Q7N:ZFH1Q\A(3!]OO8U;K=!M&[1=NQR-RE*FK*XDLJX'8@
M4=0%5_/0\D^<'U^R44,8?3477'5+J1=.+Y,[E03V,N98Q[C8W- ]P!27%TNZ
M<1-#?P'BWTY&2VBE/UTC7N)])-5S%+9QM$;\4-JVW!$>GH^U8.QBGZH:"!?4
MM<OJAH'#W*\YV_M]/^/FLL?7>7!_[Q>G%L?94/[CA\6SA3V;2 <.[A'R7]AV
M@[3!#0=KVW80$! 0'">-1 0'@(:?-GD(5^?RZWO^.<K_ $NX_C%]CL[:)X'%
M8VGWM#]@MK=;)MFCY,4G>TK;0N0P=(@?!6+]0#T%.%K@<OP"%=B/J+U B.J/
M.9@'[\N/XQ=";IWT_N!2?!X=_KL[>OO^'4+HR_>T_P!O/(J:Y9C:]8$*JLGT
M%<V$>>QPJ@8->A5%*Q)BWV?641UT,D8IN1@,'"LCQG6[JGBG P9BYD [)A'/
M7UF9CW>\01V$+'\GT6Z995A9/BHHN7[@^6WH1RX0O8WW"T@\B"."@0[@?8C=
MX2L.Z,U[5+JN:_K4M1N_G[MQ3=R;!Y>$);#)%9])S-J7%'I1R=T-H-JF)U(]
M=H1^+9,QTUW2H>4:S/2[S)Q[BR<.WMYP0VM[.0R*XBU")\AH&LD8XN,9>>3P
M\LU$ M8WBJX=2_+K)M_&S9_:,\ES9PU?)!(&B5D=27/8]@:R1L;:>SH8\,:2
M72N*KAZ@(:@.H#Q#CKJ \A#AH(#5L.!56?:8[M#P?=[E?A[.F[8^Z?9Y:K6X
MGRSS)F$!:8FOQ=T<ZCF61AH]$UEW.JNJ=19VM.6H"!72ZAA46DFKHP\! 1UF
M=>MCC9F_)I+5H;B,C6YA Y-+G?;HP.0#9*EH' 1N8.Q;(^AV]';PV1"R[>79
M6PI!*36KF@?:GDDDDE@T/<35TC'NH 0I6JA13(E$2B)1$HB41*(NL\NX?QYG
M6Q)C'&3K=:7);$P0!.@L'EO(U^D4X,YF%?IZ.8F:CCJ"9!PB8IRZB4=2&.4W
MF9?#X_.6+\=DXQ);/]]IY!S3S:X5-".PD&H)!\7<&WL1NC%R8?-PMFL9.P\V
MN'Q7L=S8]O-KAQ'J)!JT[X=A%X[3)M"XK<5G+TPM*F;)QM\+MT/E&VI=54Q
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M:T5TL8T4#6-J: #F2XU<23=O;>VL-M/$QX7!0B&QC)-*ESG./QGN<22YQ]X
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M2RFEN)RDS=$A-/"N*:65[-,WLQD_.N##4-U*N7F'Z>R;GP#=S8^IR.,C<7L
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MBF)QT3>6A<LC  =-+7IU60O;0YN?J%"H"\VF/9)@L1E?]Y#=RQ>Y-&'\_1X
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MZT]>;_/7DNV-EW#H=O1G3)<1N+7W)I[0:X4+(*U;1IK* 2XZ'!BO7T>Z&V6
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M!ZX(BBD0!.HH<  -1JVMS<V]G;27EV]L=K$QSWO<0&L:T%SG.)X -:"22:
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MGB+].G/_ !&J6_H:ZH_B6]]YOV2N/^EOIQ^-K?WI/L$_&C]O?^%GB+].G/\
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MOMV/P^#Y0I_F1Z4_SV?^C3_8+D^7?J;_ #-O\/;?QZT_$4]QW[V%B_MM6/\
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MBL?7KI1%%3WL?\FIN&_F^)]?VYL??FU-GEW_ ,7,9]1=_P!3G4)>8C_">_\
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M6B>^/ #".H<.(<=/1IKZ?&GPT1:"/, U#40$3<. =.G'CPY4 [UR@@ AIX_
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MAT,(%#4Q@ .'K&$  /A$:GHFG-08V.20Z6 N/H%?U?\ M7QYJ7@JEZ/CD_\
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MHAS :TYW$$MK.^UG:6SQO<UP/,.:2"#Z011;=K>XAN[>.ZMW!T$C&O:1R+7
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M=.YK/;S #\KG;$[CRC<:2N[SHBUR4YD-/K'I;%*!2@4H 4I0 I2@  !0 -
M #@  %:B"234\UMC  %!R6M%RE$45/>Q_P FIN&_F^)_W9L?AQJ;/+O_ (N8
MSZB[_JDZA+S$?X3W_P!\V']?ME075T!)7^9GYAP#U3:>&E;,CR)6NFVH)V5^
MC;\*].';]_<%PC^Q%C;]9L+6H#=?YT9+[_N/NSUMCVG^:N,_N^W^XL7;M> L
M@2B)1$HB41*(E$7EL3?]&9?^F;_WO]MJ\:W,6W\G9WZ&_ %I[GKXS^[4?A5U
M3Z/3^ =._P",)D7];6/ZU\>:7_$F'^ZX?NUPK]>63\P+G^]'_P!5M%.G5;E8
MI*(L&^YB@NYV ;NDVY1,<N#;W<&*!>H10:1IG3H #_<R)^/ASJ1ND3FLZFX0
MNY?A"(>Z30?-(6"=3@3T^RX'/Y#)\P5/S%YU/HT^OII^?X5M86K&O*G-7ZNR
MK*1TEVUMNR3!1,QXD<IQ<BB0P&,VD29DR ]436 !$2*+-WR2X /'H5*/(:UE
M>86&6+JYE72\I!;.:>]OR6!OS"TM]8*V1^7^6*3I/C&1BCF.N6N'<XW<[N/U
M0<'^IP4J%0LIF2B)1$HB41*(E$5 7O(Y'MG)G<0SU)6JLDZC[7=6MCQZ_1,0
MZ;NX;%M.'MZY@*8FH&&-GFCAD/$>+4>7(-GG03$WF'Z68R&^!;-,V28-/8R:
M5\D?US'-?^V6M+KEEK/+]3,E<63FN@CE;%J!K5\$<<$H-.ULL;V=O!HY=F8O
MT<P/\,++O^+C._NDXU]/'6L"\UOYA6?][1?<+E9SY7N&_)P.7X*N?N]BKFM4
M 5]$HB41*(E$2B)1$HB41*(E$2B*&+O,X81N3$%E9MC6AC36,[B3MZ=713,8
MRMG7D<K=,[HP#T^5%7.@T\L3: 0'JO$.JH5ZT81MUAX<W&W[?;R:'G_LW\J^
MIX :.^0JNGF+V\+S;MKN2%I,]E/X;Z?\&>C:GZF0,H>P.=WJMKS$.0<]>&H^
M@/#AJ 56-4X7QIZ./,> <O0'$-.'/EK7-47UH'HUT 0 = UTX!X@ >/#PTKA
M%IKX=(Z#P$N@>J.@B.F@<?37-.U$] \ U$.GAJ&F@:@ Z!IZ*(M0#GZ!TT]7
MQU\0$!$=?37!^:BGC[(EG=<KG_("R7%NPL>S6*XD$/\ ;:\].RZ)1^+ZOLK(
MQ@#4>(:^%6 Z&VE9<A?.'!K8XVGZHN<X?Z#%:/RTXX&?+9=PXAL$+3ZS(]X'
MO,K[BZY^DC7R##"FV[&Y7! -=&4;JO95KYA?,.2Q;3+!IKBEKU"F0V0S%ZN6
MHZ<ZV>^4O&F3/Y?+T-(;2*&O[](7D5_^ $\U>18S"XG$$C7+<33@?O+&1UIZ
MKEP50_P]WZO]*KSJDG9Z?U?^Y:^GPY:Z:_#X^[7*<:IQ'W_@\-/KT7-2>7-:
M>_SXB/C7"X-.WFM>7A[GYGN47/+D/0GC^;^;K1<TX\5<@^C\[N'N4,)W?M@O
M*4.[NC!"C.8L%1XNF9T^Q/<CA5(L2W*(^T+IV)<I#HF./JHLY1D@70J8!5"/
M-!L:/#;@M]X8]FFSR0+)@!P%Q& =9[!XT=.',NBD<>+E>ORT[UGS."N=JW[B
MZXL"U\))%3#(3JCYEQ\*0%U:-:&31QL_<S2PU56%9U*(E$2B)1$HB41*(MAN
MFZ+<LBVYR\+OFXRVK6MF*>SEP7!-/$8^)AXB-;G=/I"0>N#D1;-6K=,QC&,(
M  !7:LK*[R5Y%C["-\U[,\,8Q@+G/<XT#6@<225U;Z^L\99RY#(2LAL88W/D
M>\AK6,:*N<XG@ !Q*\YS?3N:E]W&Z+*N9W<G+OK;E;A?0^-6,N<Y5+?QE"O'
M3:S8A!B(BC%^9'B+QT@F'3[>[<*&$RBASFVM]-]H0;&V;9;?8QC;N.(.G+>3
M[AX!E?7F[VO9:X\=#6#@  -7/4?=LV]=X7F=<7?)GR:86N-2R%E1$T]C>%7.
M:/9:]SR*ESG.W38/M(N'>CN8L/#D<D^0M,7A;GRE<+,@A\V<;P:Z"EP/ <=)
MR-Y"7,HE&,!$!#V]ZB(AT <0^/4S?%IT_P!HW.>F+3>Z=%O&?]Y.\$,;3F0W
MC(_E[#'4XTK]>F^RKK?>ZK?"0-?\CUAT\@ I%"WB]Y)X5(&B/@09',#AI+B/
M1%LFRK5QO9]L6!8T&QMJS;,@HNV;8M^-(<C&'@X9FDPC6#<%#J+'(W:H%+UJ
M&.H<0$QS&,(B.JW(Y&]RU_-E,E(Z:_N)'22/=S<]QJXFE!Q)Y  #D  MH%A8
MVF,LHL=81MBLH(VL8P<FM:* <:D\.TDD\R25RBNDNVE$2B)1$HB41*(E$2B)
M1%6W[\^P5G>]BCO.Q1:P#?\ 8Q6K3.;>&;*G=W9CQ%HWC8R]G;5N!_:)/'@-
MD47;@"=?R&<RBQ_)CTP+;;RT=3I,?D?R S<W_IEQ4V9>12.8DN="">39JES&
MU_=AI:-4Q54?,=TVAO+ []PT(%_%07FD&KX@T,9.0 :NBHV.1U!2'2][Q';@
M*H:/$.(<]0$!#F'H]ZKT*DH<6D/'!P/_ +5>5['^[UUN+VK)X\OZ]_G-F+!T
MN[M>23F'Q%[KE<<J@V=6+<CSS#>U23-FBZ5A1=&ZU1/&E%<PJ*E.IKD\Q>Q&
M;4WH<KC+?P<#D6"1I8*1MG%1-&.QI-!+I'#VSIX-(;L.\ON]_P J-G#%W\[I
M<WCW&-P>07NAX>$^M:N:VIBJ[VAH&NNIKGS2U7Q3TE$7G"]P;\.G=]_C&Y<]
M !QO26TX5MCZ8?X<X+^Z;3[A&M5G4?\ /S,_WM>_UN==&P.'LA71BZ^<Q6];
MSR9L;&MQ6E;=]24:@N\4ME>^&-RN[<DY=!!)064 [/:;IN=Z<2H).C()',!U
MT@-DEUGL799BVP5W*V/(W<4DD+7$#Q!"8Q(UI)&IX\5KM JXMU.'!KJ>!:8/
M+7N+GS-G$Z2PM9(V2.8"XL=*V1S"X!ITL(B>-9(;K#6?&>P.E]V*=\'.6VQ"
M!QOG5H]SMA6*:L8B-4.JT:Y1L:'8-2,F;2WIUP9LSNF,9-TB@5E+F\[I*!$G
MJ*90)4$]2/+IMS=SY<MMQS<;N![BYU 3;RN<:DR,%3&XD_'BX<R8WDU4Z=/?
M,+N'; CQNXP[(81C0T5H)XPT4:&2$@.H!\66NHTI)$ :V#L9=[+MWY(:%4=Y
MADL:2!C)D&&R;9-S0CH@J '$TG#L+AM@2$,/282OQ --?BB C5S,>7CJGB7D
M1V,=Y#Q]N":-P^M>8Y/]#YJLKB.O_3/*M DNY;2<@'1-#)45[WPB6(?PGIY4
M*RBB>X'L9FDTE66[O;F0JQ0.0LEE^QX58 , B *-YF:8+HF  XE.4I@\0K#9
MNEO4B D/P65-/H;:9X]]C7 ^XLL9U2Z;OI7.XIA/8^YBC/NA[FD>ZN3I;T]G
M"XB5#=GMG6,4-1!+/&+5! -=-1 EU"(!K73=T]W^P5?@\P!Z;*Y'_=KNQ]0]
M@2DB+.8=Q'=>VQ^"1?T4WG;/42B=7==MK2( @ G4SKB\A0$1T !,:Z0 !$:_
M(Z?[]<:-PF7)^\[C^+7[?O\ V)&TODS>(:P=IO+<#WS(N+S?< V.6\@+B1W=
M;<SD#J]2+S!8T\X]0 $0!I!34DZ$?6#0 )J(\J[MOTNZCW)TQX++#ZNUFC'O
MO8T?-71DZH=.8Q7\.8IY'9'<Q2GWHW./S%A+F[OK;#\6QDL%DW;<F<KK9H*%
MCK?L&V)N/B7S_I#R$75Y77'PL&V8"8?MCAM[<8A $2)*&T(:0]N^6WJ3F9HS
MD88<=9./M/FD8YP';2*)SW%W<UQ8#VN:.*P+/^8KIYB(9!CI)\A>LX!D<;XV
MDFG.29K 6"M7.C;*:5TM<1157]]_<>SIOUN5@>_/DZS\8VQ(K2-C8FMPYEX6
M#>*MU61IN8F'""$E=%T+,%C)&=K D@B0YRMF[<JBH*7/Z:])MM]-+1PQNJ?+
MS-TRW,G![Q6NEK02V.,$5#14DTUO>0TBGO47JMN+J+<-;D2V'%1NU1V[/B,-
M"-1<0'O>0:%SB!VMCC!+5T=M(VVWSNMSYCK#UE0$K+I7!<\*6\91BU7,QM&Q
MR2"!KINF;?)D%",8Q4.58Q#*&(+AQY:"74LJF0V1[YW;C=E[9N\[D961NBA?
MX37$5EETGPXV#FYSG4%!R%7.HT.(Q_8VU,AO#<MIB;.&66&2=@E<P<(XM0\1
M[G<FM8VI)/=I;5[FM=Z1MN6[!VA;T%:=L1;.#MNV(:,MZWX6/2!!A$0D,R0C
MHJ,9(AP2:,&+9-),OV)"@%:E[R[N;^[EOKU[I;R:1TDCW&KG/>2YSB>TN<23
MZ2MJ-G9VN/M(K"QC;%901MCC8T4:QC &M:T=@:T  =P6]5UUV4HB415I^_ML
M6:79:$7O,QC;+QQ?-KKQUKYJ:P4:Z?*W!8YVWLENWQ(H,R*F*ZLARV28.7 I
MCU1KM,53E28DJW7EDZDR65\_8&8F:,=,'26A>X ,EK62$$]DH)>UM>#VNH"9
M"JH>8_IPR]LAOO#0UR$5&78:'$OC #63$"HK& &/) +HRRK@(6M-4*S+TNW'
M=TP5\6'<LW9]X6R_3E+>N>W)%U$S40_2 Q2.6$BR41<H'%(YB&Z3:'3.8A@$
MIA ;L9#'V.5LI,=DH8[BPF:6OC>T.8YI["#4$=OKIVJF>/R.0P]]'D,?+)!?
M0O#F/:2US7 \.//]7'N5FW:-](=^3XN"LK>)CR1DW+%LVCU\RXS3:JO)($$2
MHED[LQZY,Q1*_7$H'=.(ET"9SF,*3!,-"54#?7E8\6:7(;#NF,8YQ=\EGKI;
M7CIBF&HT[&MD:2!35*>:MIL?S..9#'8;WMC(YK0TW,- ]U.&J2$Z6$TH7/8]
ME373". ,RM@=V/MYY&;%<1.YVPX)0= 49W^G.8Z=(G$!]0WSVB8-NKH(:"9)
M10GH-Q"H"RG1#JEB7Z)\/<2CL,)9.#_!/>1ZB ?0IUQ?6GIGEHR^'*Q14-")
MF204(],K&M(]+7%O<5W@UWP[+GI"*-MW.V50%.D"%^[OB]-01/ITE%)2Z"*E
M,;7@ E :QV3IQU"B)#\%F!3_ ,'<$>^(Z+W(^I73J6GAY[#$DTI\MM@:]U#)
M6ON+<OWY6T'^%7MN_;RQA_VHKX?D!OO\29?^AW'\6NW^7>Q^7X9Q5?ONW_C%
M_)7>AL[0*!UMV&VE$HCT@97.V+DRB.@CH GND UT"OTWI]OUYHW!Y@GT6=Q_
M%KYR=0=A1-U2YO$-;WF\MP/FR+A=Q=Q#8G:[91U*;N-ORR:8"8Q(+)]JW4Z$
M +U>HQM>1F'JHZ>!4Q$1X<Z]&UZ4]2KMX9%@LFTG_B6\D0]^4, ]]>?-U4Z;
MPL+_ ,-XV0#GX4[)C];$7GYBCTW =_S9SC>.F&.&VUZ9ZO%%NX2AS1,"\L^P
MC2()J%0-*W+=J49,^P$< '49C%O!4)KT#R-4I;7\L6_,M-')N!UOC; D%VIX
MEFT]NED6J.M/HY6T/,=BC3<OF4V3BX7LP+)\A>T<&G288M0J!K,E)@*CFV%P
M(X@@<54WW3[P<^;R;\)?F=;R5GUX[Y02M2UXY (JS+'C9%9!5S%VE )**ILD
MEP:(%7<K'</WGD)BY<+&3();N;,V)MG8.-.,VW;B)CM)DD<=4LSF@@.E?0:B
M*FC0&L;J=H:T$A4NWAO?<F^LD,CN*<RR,:0Q@&B*,$U(BC!(:#P!)+GN#6>(
M][FARR![7NS2\]W>Z/'K1&WWY\28\N>%OC+=UKL'(V\U@+:D&<N6SC2/05H>
MX+V6138MVQ3BX*@LLZZ!2;J"&+]9-_8_8VS;J1TK?PW=0OAMHPX:R^1I;XNG
MGHBXO<XC34!E0Y[:Y3T>V-D=X[OM"R)WX)MIFRS2EA,;61.:\L+N#=<G!C!7
M55WB:7,CDIZ#E:N5LR2B)1%^&3C(Z:C9"&EV+63B99B[C)2-?()NF,A'/VZC
M5ZQ>-EBG1<-7;94R:B9P$IR&$! 0&OK#--;3,N+=SF3QN#FN::%KFFH((X@@
M@$'L*^4\,-S"^WN&M?!(TM<UPJ'-<*%I!X$$$@@\PO.DWX[0+]V:;AKZQS<=
MNR+.R'5PS$KB6ZC-G9X*[+ >O5W5OJ,)98@H.9B)C54VDFW!0RK5ZD<#:D,F
MH?:STTWWC-_;6MLK:2L=D!$UMS'4:XYP '@M'$-<X%T9H YA!X&H&KWJ1L;)
M['W-<V-Q ]F.,SW6[_:<Q\)=5A$CN)=I+0\$DL?J82ZFIW7^V?=MG_:'>BE[
MX&O^1M!X_-'DN6#432D[1O-A&+++-8V[;:?%4CY9ND5VN1%8 3>M"N%1;+H'
M.8]>IN_9&V=]8X8[<MJRXC;J\-_Q9(BX4+HY!1S3P!(KH<6MUM<  O(VEO3<
M>R<B<CMZY?!([2)&BA9*UKM0;(QP<UPY@$C6T/?X;F.<7*V3MO[_ 'M+R;'0
ML5G)C=. [W5;-T9=X]B7=V8V6D?*(5=:*N&W22$\Q9.' &,4LA'(%0(8I3+*
M:&/5(MV>6+>^(EDFVXZ')X\$EH#A%.&]FIC],9('T$A+B.#!4!72VOYD]FY6
M)D6X&38^]( <X-,L)<>'LEE9AQXG5%I:#^Z.H2)*;?W\[(;G;$=1&[?;J8BG
M3THR.7[%@GWKAJ4#1LY-QT@0VG,#) (#P'C42773'J+9N+9\'E>':VUF>WZY
MC'-^:I3M^IO3NYH(\YBVO/)K[F*-Q_:2.:[YBY=^^^VF='F?OH=NW0)>L#_=
MLQKT"00ZNOJ^<VG3T\=>6E>?^0N]ZT_ V5K]Z7'\6O4_+/9Y;K&6QNFE:_*H
M*4[_ (ZVEQO<V8M!$'.[C;(B8-=2*9XQ:!PT+U?$^=77\7CRXUV&=.>H,G&/
M!9@C[RN?XM="7J1T\@.F;/89KNXWML#[WB57&7O<*V*L"'.XW>;=C F7J,#3
M+5F2!Q#I$VA$V$LY.J;0.10$=>&FO"NXSI7U*DY8+*CUVTK?]9H76_2ETXI5
MF<QCZ?0W$;_]5QK[BQ\R'WF^W7CUFHN.>D+V>DZP3B,>6C>%SO%Q(7J$$WI(
M5I )]6N@"J]3 1Y#P'3*,5T ZJY1^G\&_)X_HII8F ?M0]TGO,*QO)]>.F.,
M%/E[IY:&C8H936G<]S&15[@9!7W"H0=Z7T@#).2F4G8>T*W)/#UK/D!:/<H7
M8G&NLJO$E04(Z3MR*9.I:W;*352/T@Z\Z0D"\%$%&BH 8+%=/O+#B,1(S);Y
ME9D+QIJ+>/4+8'L+R0V24CGI(C9V.;(U5^WYYE<ME(W6&RXWV%N:5F?H=<'C
MQ H9(HP14'29'T.IDL;@JZ#APN[<.';M=9T[=+K.G;IPJ==PX<N%#*KN%UE#
M&46776.)SG,(F,81$1U&K6,8V-HCC #&@  <  .X=@HJM/>^5Y>\ETCCQ/,U
M_5R[E;"^CZ[+&L1;ES;T+_@UBW#..)"Q,*)RC%=N:.MA%N1.\KZC//*";CYT
M.G/R2U<$ !3;L7A2B)'(U27S0]0GSW4/3_&2#Y+&&S79:0=3ZUBA=3B/#IXK
MFG@2Z,\"Q71\M73T6UO)OK*Q$7+R8[4.!!:TBDLPXT]L$11F@<T"85+9!2SG
M5/5;9*(E$45/>Q_R:FX;^;XG^'^W-C^IL\N_^+F,^HN_ZI.H2\Q%?T3W]/YS
M8?U^V5!=7]#5_F9PY?ZGW/16S(\O<6NFV_E+/JQ\(7IP[?O[@N$?V(L;?K,A
M:U ;J_.C)??]Q]V>ML>T_P U<9_=]O\ <6+MVO 60)1$HB41*(E$2B+RV9O^
MC,N/_P S?Z\?_>E1^#6MS%O_ "=GU#?@"T]S_NSS],?A5U/Z/3^ =._XPF1?
MUM8_K7QYI?\ $B'^ZH?NMPK]>63\P+G^]'_U6T4Z=5N5BDHBX)E''T%EK&F0
M<6W.F92W,CV5=%C3I"<%/DJZH5[!OS(F 2B19-L^,8A@$!*< $! 0KT\+E;G
M!9BUS5G_ "NTN(YF=VJ-X>*^@D4/H7F9O%6^=P]UA;NOR:[MY(74X$-D86$@
MBA! -00:@KS3\T8?OC >4[YP_D:(=P]W6!<<G;TFBZ;+-TWQ6#I5%G-QIEDT
MP>0DZS*1VR<$U2<-5B'((E$!K;EM[.X[<N%MLYB9&R6-S$U[2"#34*EKJ$T>
MP^R]O-K@0>(6J3<.$R.WLQ<8C*1F.\@E<UP((%6D@EM0-3#S8ZE'L+7M]EP)
MD/[97= OG8C=A[4N=&4O?;?=LJ9_>-CLP;K3=L2SA%!LI>]@F>.&;=.8\EJD
M1XQ563:2*"8 (I+E36+%G5_HYCNI-B+VS++;=<#-,4QJ&/:"3X4U 265)+7
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M%(0H 4I0    "J=/>^5YEE)=(XDDDU))XDDGB23Q)/-6YCC9$QL430V)H
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MAX>BN:47*M_]M*SC69LLPLW62,D[N*-G+U= <.D3!=MS3$U'F ! ! HP[EL
M>X'HJY/36S-ELRS8[X\@>\^D/>XM/UFE; >C./=CNFV,8\$231OF(_?I'R-_
MT'-5,?NRY(6R=W"]S4P9<%FMN7LWQS' 7BD@VQO!15G.4D^D=-#2T2Y4,/BH
MH:MPG1'$C#]+L/ &T?+;>.[O)N'NF!/[5X'J 5%^LV6_"_4C*W(=JC;=.B'<
MWY.&VQ IV5AKV^TYW80!'5Z/J^#GZ0J55%W-.?+ZORJY2E>2<=/J]SW:)4TX
M\D\?J]'+GK1<'GZ$]SA[H47/+@@>C7ZO>K@(.5$\/K:\/RN-<E<<*+^K===J
MN@Z:KJMG+59)PV<H*'0<-G""A54%T%DC%51714(!B'*(&*8 $! 0"OR]C)&F
M-X#F$4(/$$'@11?6*62%XEB<6O!X$<#P*E%P[WF.X+AN,:0;;,Q,C0;!)-)G
M'Y<MZ,OET1-, * +74L5A?+T!(4"Z+RJ@% /5T'4:AK/] NF&X)G73\?\DNG
MDDNMGNA''NB%81[D8]-5,&W>O'4;;L(M?EORNT:T!K;D>,X4[?%=]N=4<"'2
M.% -(!K65/ 'TCP1*RB=SV!2^:9R1-W>^$Y$Q6Z;4YP**RN/[RD%W'6W(/4<
MR4Z?S/L4B\ J%]S^4X>U/L_)$"G"&[;7C3_CQ <SR!@X=KBIAVSYI7DB'=F/
M817]UMG%IXGEX$I<#04J_P"4-U&OL-%%/QMHWI;9]WD2]DL!Y3A;S=Q#=)S/
MVPJB_@;SMY%8Y42K3%ISS6.FV[(7!O**[(BHS44X)K'X56/=_3W=^Q9FQ;FL
MY((Y#1D@+7Q/-*T;(PN;JIQT$AX'-H5D]I;^VGO>)TFW+MLTL8J^-S71RM%=
M-3&\-<65X"1H=&[AI<:A92UA:S%*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)
M1$HB41*(E$2B)1$HB41*(OSNV;1^W4:OFK=XU5#I5;.T$G#=4-==%$5BG3.&
MOI :_<<DD3Q)$XM>.1!((]T+\21QRL,<K6N8>8(!!]PKK-_@O"4HN+J3P[BN
M1<FUZG#_ ![:3Q<W4/4;59Q$**#U&'4>/$:]F+<VY(&Z(<A?,9W-GE ]X/7B
MR[7VU.[7/CK%[^]T$1/OEB^&V!L&LQ.+3#&*&HJ=(*"VQU:" J 3J$H'%*'*
M)^D3#IKRU&N7[HW+)PDR-\X#OGE/PO7#-K;8CXQXZP;7NMXA\#%N;;$.)V8G
M,TQ?CMJ90  YFUE6T@)P*(B4#BE&%$P%$1TUY:U\'Y_.R"DE[=N'IFD/PN7W
M9M_ Q_N=E:-KW0QCX&KD\7:]LP9NN$MV"AS] )]47$1\>;H+U=).IHW1'H+U
M#H'(-1KISWU[<BES-+(/IGN=\)*[L%C96QU6T,4;OI6-;\ "WVNJNTE$2B)1
M$HB41*(E$2B)1%\F(4Y3$.4IR& 2F(8 ,4Q1X"!BB @(#7()!J.!7! <*'B%
MQ5Y85C2)Q4D++M-\H8_F&.\MR'<G,IIT]8F79G$3]/#7GI7>CRN3B%(KF=H]
M$CQ\!70DQ.+E-9;:W<?3&P_"%LKC#V)'1_-=8MQRY4 H%!1Q9%LK'Z0UT+UJ
M1AC=(:CP]VNPW<&>8-++Z[#?1-(/]I==^WL!(=3[&S+O3#&?]E?T;8DQ2RZ@
M9XRQZT XE,8&UEVVAU&+P*8WE1I-1+X#X5P_/9R3]TO;MWKFD/PN7Z9@,%'^
MYV5HWU0QCX&KE\="0T.!RQ$1&195.!RQS!JQ X=0FT.#9)(#>L81X^(UT)KJ
MYN.-Q(^0CZ)Q=\)*[\-K;6W\GCCCK]"T-^ !;G7P7W2B)1$HB41*(E$2B)1$
MHBVV1A8>7*4LM$QLF4H=)2R+!J]*4HF PE*#E)4  3  Z>D*^\-S<V_\GD>S
MZEQ;\!"^$UK;7'"XC9(/IFAWP@KBKG%F,7A5".\<V&Z(L/4J1S:%OKE5-U ?
MJ4*K'& X]8:ZCKQXUW6YO-,(++RZ!'=+(/\ :72?@\)("'V=JX'G6*,U_P!%
M?D0P[B)JH"K;%F.&ZH ( JA8]LHJ !N @!TXLI@ 0Y\:_;MP9YXTOOKLM],T
MA_VE\V[>P##J98V8=WB&,?[*WAMCZPF0]3.R+0:& X* 9M;4,@('+\4^J3(@
M]9? >85\'Y;*R<'W-PX>F1Y_7789B,5&:LM;=I]$;!_LKEB:::)"II)D23(&
MA$TRE(0H:ZZ%*4 *4-1\*Z#G.<=3B2X]Z[[6M:-+0 T=@7W7"Y2B)1$HB41*
M(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41;=)1$3,)%0EXN.E4"")BHR
M3)L^2*8=-3%3=)*D 1T#B >%?:&XN+9VNW>^-W>UQ:?F$+XS6UO<MT7$;)&C
ML<T.'S05PMQA_$CLX*.L6XZ<J%*!"J.+(ME8X% 1$"@92,,8"@(CPY5Z+-P9
MZ,49>W;1Z)I!_M+S7[>P$AJ^QLW'TPQG_97\/N*X;^]+C/\ L#M;]2O=K]?E
M'N'^?WO\/+]DOS^3>W?YA9?P$7V*_0WQ!B9F8QVF+\=M3G+TF.WLFVD#&+KK
MTF,E&%$2Z\=/37Y?G\[(*27MVX>F:0_"Y?MFW\#'QCL;-I/=#&/@:MZ96+9$
M:(&CK.M5@8IA.4S*WHAJ)3CIJ8!09IB!AZ0X\^%=:3*9.84EN)W#TR//PE=B
M/%8R(UBMH&D=T;!\ 7*"$*0I2$*4A"@!2D( %*4 Y 4H    5TB234\2N\ &
MBC10+ZKA<I1$HB41*(E$2B)1$HB41*(E$2B)1$HBJ#=QK<#';@]S5RRMM/!=
MV78+!#'%K.]!*C(HP#Q\XG9E H&T,WD+D?N@04X"JT21,.G  ISU*W#'N'<\
MLMN=5E T11D?/!M2YW[9[G%I[6Z?4-?_ %@W;#NW><TUDXNQEHT6\1[':"XR
M/ [G2%P!^>:UI[E@?Q 1'@  /'74->>O+@(:CSTJ/^')1:M/#0O 1$P>/O<=
M0U = KGUKE:@(!S,8=-?=#0  =1X:>/#QXUPN$X\-3"/$.0:"&H#ST#7EX5S
MP1!Y@'5RT]\== XCQ'4=?0%.RJ+>[8MJ3O.YK<LV%3,O,7;/P]KQ:(<!/(W!
M(MXQF' 0 "^>Z*(CX!J/(*[5E;2WEY%:P &>21K6CL+G$-:/=) 79L[*?)7D
M..MA6XN)61-'TTC@P?-*O-PT="XQQ[%Q*72VM['UG,F!!(0I"H0]JPJ;<#%(
M'24H)LV.NG"K[XK'"&*VQ-H.#6QPL'J 8T? MG-O#;X;%1V[.%K:V[6BG8V)
M@'P-7F/WM=<A?MYWA?4JJJM*7K=-PW;(JK*&464?7),/)IV910Q0.H<5WIM3
M#Q'QK<MCK.+&X^#'P """%D;>SV6-#6\.S@ M2F2NY[^_FO;G^52O+G\:^VX
MU?QIQJXDU[>9YKC'I_/U]/C[NE=SU+HE.7H^KE^57/K3EQ3PTY?5^37"<::>
MU/R_R:+GX?FI^=XZ_#PKE<<_>_5^KU)]7P>]\-<)\*>'/ZWA\'A3U)4TXE/$
M/JTY<QHN10$=Z>@-?<][W_=HN/0NQ,5XER5G"^83&N);*G[^O>X'":$;;]NL
M57KH2'5(FH_?J@!&D1#LQ.!G+YVH@S:IZG65(0!,'EYG-XC;N.DRV;N(K;'1
M"KGO( Y'@.USS3V6-!<X\&M)-%ZF)PF6W!?QXS#6\EQ?2NHUC!5QX@$T[&MJ
M"]YHQ@.I[FM!<+@W:5[25Y[-KPE=P&=;JB7>5I6U)*SK=L*SGJLA;]I0DV[B
MWLL_N&>.@U+/7*Z&*3130;%%@S2$Y@5<J*$,WH?UPZXX_?U@S;&W('C#LG;*
M^:4:7R.8'!K8V5.B,:BXN=[;C0:6 '7>;HQT5R.PLC)N'/7#'9%\+HF0Q&K&
MAQ:7/D>0-3_9TM8WV6@N<YSW.:(I\*K*K'I1$HB41*(E$2B)1$HB41*(E$2B
M)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*
M(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$
MHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$
M2B)1$HB41*(E$2B)1%@MW%,^R6WS;'=<Y;CA%M>5ZNF^.K4<**B1:/>W&T?&
ME)IJ0@^89W"V^R=KH&^(1T5(3<. X'U(W!)M[:\L]N:7D[A"P]K2\.+G#CS:
MP.TGL=I)!' QEU<W5-M/95Q=6;@W(W!%O$2:$.D!U/;WN9&'N;V:@*JGZ4HE
M*4@ /JAP$QNH0T\1U PB81#W1]VJ;DU)<5KZ  %!R6H<##P]/'F//F @'4(\
M>/HK@\D[%KPTYCIU>D!UX:Z"(<QX<.-.-?2B<QT\=- +J(!R#@.G ?'E3EQ1
M:> !H AU &O#D(#QXAH(@/CXT1:AIIP >.A1^ ?#GPX_!7!12 =L/%Y,F[P<
M=JN"*&C<;MY7*#\"%*<H*VVFBS@@.8VH)E)<LPR-KS]3AH(ZU(W2W%_A/>-N
M7<8K<&8\/^'32?X0L4K]%<(,UU"LW/KX%DU]R[UQ@-9_\Q[#[BLM;Q+O)8&T
MS<Q>9E"I*6Y@;+$FT$Q_+!211L:<"+;@?F4[J1,DF7QZCA5[=@V!RF^,/CQR
MER=LT^AOC,U'W&U/N*Z6^,E^!]FY7)TU.@Q]P]K>6IPB=H;7O<ZC1Z2O-4X:
M<N'^EI[@<*VX^@+5"YVLE[NTU/NIZ/K_ )/P:<*'FOSQHG/Z^OY_Y-$XGAZ4
M'E^51#R]"<_JT^KE3M]"XXGUIR][ZN&GOT7(X<>Q/R/JX> 4[5SPIW!/J#T>
MYK1<</=3\WW ]S\JN4]7:N[-MF'AW!9_P[A )PEM$RGD*V[+6N [<'HPS.9D
M$T'TDBQ,NV*^=-F?F&00%1,%E@*03E PF#'-VY[\F-L7^X?#,IL[624,K346
M-)#2:&@) !-#05-#2BR+:>#&Y-R66"U^&VZNHHBX_.MDD:QS@.T@.) X:B V
MK:ZAZ$&T39E@_97C1OCG#D =-1<_M=U7Q.%9/;YO>5-IU/[DFFS-GYJ*.G2V
M9HD19M$^"213&.8^KG?6_P#<?4'+G*YZ7V1PCA940PM[HV$GB?GGDESCS-
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M<[[F9:,3L&T)%K9SR3,PE<FS;19G94&D@;_E!0)!841FW;$O 6; 5UQ5$I3
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M.L'&YOLF6D-$;(P>PZG%Q />- KZVJT'EJQ\IN\KE7-^TMCAA:[Z8E[WM!]
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MB!B%34.V\PZK9;35IU8Z?7/3K=DV+#7G#2DR6LCAP?$:'07<B^(G0_D30/H
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MA%)')&YS6\7%I>T-=0<2T.+J5-* D?K=G2/?.SK Y/,V;FXT$ RM?%(UI)H
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M(LV+!DU2*@U9LVC<B;=JU;(D*1-,A2D(4     JRL44<,;886M9$P -:
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M"28%(DBBF4"E*4  I0  JT[&-C:&, #&B@ X  <@!V *[;&-8T,8 & 4 '
M#D .X+^]?I?I*(E$2B*D1N:NY*_=QN=;Q;]0M)[*]\.6(B(&$8YM./(^.T.
MAU!["T3T$- T&J-;KO/E^Y+VZ!]A]U*6]OLF1Q;_ *-%K2WI?MRF\,KD6?$E
MR$Q'U(>6-_T6A9^]G_!2E_9[E\PR*1#6]A:+$&8+)"<KR];O8R$9%%2ZQZ &
M&A2/'!QXF3540'0-0$)#Z.8%U_GG9F4?\O9MJ/3)('-;Z" -;CW$,/;52MY?
M=L'+;KDW#,/^4QD?L\.<TS7-;]8S6X]H+F*SU5HE==*(E$2B)1%6V^D/;6)B
M]<:8YW76R1-<,.D7L3)#$K<YWA[0O&<CAM6?37+ZI&=N74Y6;+IF 1-\L%4
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M2B)1$HBCW[H606EA[-\D-5A/[=?[F Q]$E()0 R\S*)2$EYFHZBD6W8=Z(@
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MF3L:QI;SX>*P>*T-'%S9W.H:%V\_1PW EW19T:= =*^ SN1/KQ*+;(=F)@4
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MWS=?8KO-Z5=88QICW._3]\77V)^%?#G83W+'B8(NM[!ED@,!^@<KY@3]<H&
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J(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(O_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
